


Biomaterials Science

Volume 11
Number 9
7 May 2023
Pages 2963-3368

rsc.li/biomaterials-science



ISSN 2047-4849



REVIEW ARTICLE

Wojciech Świączkowski, Silvia Farè *et al.*
In vitro functional models for human
liver diseases and drug screening:
beyond animal testing



REVIEW

View Article Online
View Journal | View Issue

Cite this: *Biomater. Sci.*, 2023, **11**, 2988

In vitro functional models for human liver diseases and drug screening: beyond animal testing

Alessia Paradiso,^a Marina Volpi,^{†a} Chiara Rinoldi,^b Nehar Celikkin,^c Nicola Contessi Negrini,^d Muge Bilgen,^c Giorgio Dallera,^d Filippo Pierini,^b Marco Costantini,^c Wojciech Świążkowski^{ID} *^a and Silvia Farè^{ID} *^{d,e}

Liver is one of the most important and complex organs in the human body, being characterized by a sophisticated microarchitecture and responsible for key physiological functions. Despite its remarkable ability to regenerate, acute liver failure and chronic liver diseases are major causes of morbidity and mortality worldwide. Therefore, understanding the molecular mechanisms underlying such liver disorders is critical for the successful development of novel therapeutics. In this frame, preclinical animal models have been portrayed as the most commonly used tool to address such issues. However, due to significant species differences in liver architecture, regenerative capacity, disease progression, inflammatory markers, metabolism rates, and drug response, animal models cannot fully recapitulate the complexity of human liver metabolism. As a result, translational research to model human liver diseases and drug screening platforms may yield limited results, leading to failure scenarios. To overcome this impasse, over the last decade, 3D human liver *in vitro* models have been proposed as an alternative to pre-clinical animal models. These systems have been successfully employed for the investigation of the etiology and dynamics of liver diseases, for drug screening, and – more recently – to design patient-tailored therapies, resulting in potentially higher efficacy and reduced costs compared to other methods. Here, we review the most recent advances in this rapidly evolving field with particular attention to organoid cultures, liver-on-a-chip platforms, and engineered scaffold-based approaches.

Received 6th December 2021,
Accepted 26th November 2022

DOI: 10.1039/d1bm01872h

rsc.li/biomaterials-science

1. Introduction

Three-dimensional (3D) *in vitro* models have become essential tools for understanding fundamental biophysical and molecular mechanisms of human biology. These systems have been recently proposed to recapitulate several tissues and organs, including kidney,^{1,2} lung,^{3,4} heart,^{5,6} and skeletal muscles,^{7,8} covering a broad spectrum of biomedical applications.

To date, *in vitro* liver models have gained popularity due to the liver's critical role in various physiological processes – such as the regulation of fat metabolism, long-term mineral and vitamin storage, detoxification, and monitoring of innate and adaptive immunity – and increased mortality rates in the

event of liver failure. Recent statistics, in fact, have shown that acute liver failure and chronic liver diseases (CLD) represent major causes of morbidity and death worldwide, causing approximately 2 million deaths (3.5% of total deaths) annually. Unfortunately, these figures are expected to continue rising due to the increasing obesity rate and alcohol consumption.⁹ As a result, understanding the molecular mechanisms underlying liver function and failure is critical for developing novel therapeutic strategies.

From a cellular and architectural point of view, the liver is shaped in a unique micro- and macro-architecture containing a variety of specialized cell types. Hepatocytes constitute the primary cell population fulfilling most of the liver functions. Other cell types include Kupffer cells, stellate cells, endothelial cells, and lymphocytes.^{10,11} Regarding its native architecture, the liver is microscopically arranged into hexagonal spatial units called lobules where hepatocytes line up in radial cords, separated by sinusoid branches of microvascular channels (Fig. 1). Such unique spatial and heterogeneous cellular organization generate a graded microenvironment enabling various metabolic functions to simultaneously occur in localized zones of the lobule.¹² Another notable feature of the liver is its extraordinary regenerative capacity which allows vulnerable

^aFaculty of Materials Science and Engineering, Warsaw University of Technology, Warsaw, Poland. E-mail: wojciech.swiazkowski@pw.edu.pl

^bInstitute of Fundamental Technological Research, Polish Academy of Sciences, Warsaw, Poland

^cInstitute of Physical Chemistry, Polish Academy of Sciences, Warsaw, Poland

^dDepartment of Chemistry, Materials and Chemical Engineering "G. Natta", Politecnico di Milano, Milan, Italy. E-mail: silvia.fare@polimi.it

^eINSTM, National Consortium of Materials Science and Technology, Local Unit Politecnico di Milano, Milan, Italy

[†]These authors equally contributed to this work.





Fig. 1 Human liver architecture and signaling. The hexagonal hepatic lobules are composed of sheets of hepatocytes radiating from a central vein towards six portal triads. Each portal triad is composed of a portal vein, a hepatic artery, and a bile duct. The lobule layers are mainly formed of hepatocytes along with endothelial cells, stellate cells, and Kupffer cells.

liver tissue to be fully replaced upon re-organization of the heterogeneous cell population – in particular hepatocytes and epithelial cells – restoring the hepatic functions required for body homeostasis.^{13–15}

Without a doubt, thoroughly recapitulating such complex biological processes within an *in vitro* liver model is currently out of our possibilities. Nevertheless, several *in vitro* assays and pre-clinical animal models have been developed to study further the liver's physiological functions, biomolecular mechanisms, and pathology development.^{16–20} Among *in vitro* models, 2D monolayer cultures (2DMCs) have been the most commonly used strategies due to their cost-efficacy, reproducibility, ease-to-perform, and easy-to-scale protocols.²¹ Despite the significant advantages of 2DMC, they also exhibit several limitations. For instance, the evaluation of specific hepatofunctionality is possible only in short-term studies (e.g., 24–48 h) as cells progressively tend to lose their polarity and dedifferentiate into fibroblast-like cells.^{22,23} Along with 2DMCs, animal and humanized animal models are also relevant tools for modeling liver disease and accessing drug discovery processes. In this frame, rodents have been conventionally used for research and development purposes. However, such models cannot thoroughly recapitulate human liver architecture and functions, being thus poorly reliable for many diseases and hepatotoxicity studies.^{24,25} Herein, the development

of 3D biomimetic human liver models for *in vitro* research is considered a promising bridge between 2DMCs and pre-clinical animal testing for drug screening, as well as for the investigation of CLD and the efficient design of patient-tailored therapies in liver diseases.²⁶

In this review, we present an overview of the current state-of-the-art on main strategies for 3D liver model biofabrication. Specifically, engineered liver tissue constructs such as organoids,²⁷ liver-on-a-chip platforms,^{28,29} and 3D scaffold-based constructs are thoroughly described (Fig. 2).^{30–32} Key advantages together with ongoing challenges and future outlooks of the current liver models are highlighted, especially from 3D manufacturing and biomaterials perspectives.

2. Liver organoid models

Organoids are self-assembling 3D cell culture systems that recapitulate tissue-specific architectures, functionality, and spatial arrangement,^{33,34} promoting organ-specific cellular self-organization. Organoids are obtained from either tissue-specific progenitor cells or stem cells that are able to self-assemble in organ-specific cell types upon cell sorting and spatially restricted lineage commitment as in the *in vivo* organ.^{33,35} Moreover, they can be formed either in an extra-






Fig. 2 Representative scheme of relevant elements for developing *in vitro* functional human liver disease and drug screening models. The schematic represents the different strategies reported in this review to implement liver models, including Organoids (ECM-based and scaffold-free structures), liver-on-a-chip (OrganoPlate, TASCL, and LAMPS), and 3D scaffolds (3D printing, 3D bioprinting, and electrospinning techniques). The possibility of applying the models as static and dynamic systems is displayed. Additionally, various alternatives related to possible bioactive molecules (e.g., anti-tumor drugs, anti-fungal drugs, anti-inflammatory drugs, immunosuppressive drugs, mutant cystic fibrosis transmembrane conductance regulator (CFTR), and calcium-channel blockers) as well as parenchymal (e.g., hepatocytes, hepatoma cells, stem cell-derived hepatocytes) and not parenchymal (e.g., Kupffer cells, stellate cells, endothelial cells, cholangiocytes) cell types have been explored in the reported liver models. The design, optimization, and combination of the components have made possible the successful modeling of various liver disease models and liver drug screening platforms described in this review.

cellular environment or without using supportive biomaterials (*i.e.*, spheroids).^{36,37} To date, the gold standard biomaterials used for organoid cultures is Matrigel.^{38,39} However, alternative materials such as collagen, laminin, fibrin, and cellulose nanofibril as supporting hydrogel-based scaffolds^{40–42} have gained significant attention due to their prominent features promoting the organoid formation and survival.^{43–45} In liver

tissue engineering (LTE), 3D liver organoids are considered to mimic the miniaturized *in vivo*-like complex functionalities of healthy liver tissue, but also to model pathological liver conditions for the investigation of human diseases. Herein, stem cells, including induced pluripotent stem cells (iPSCs) and primary liver cells (e.g., primary human hepatocytes (PHH)), can be used to target functional patterns where cells are



encouraged to self-assemble into functional 3D aggregates (Fig. 3A).^{46–52} Indeed, the self-organization ability of stem cells is crucial to boost the organ-specific mimicking, thus allowing for the generation of 3D constructs more stable than 2D cultures upon maturation of selected cell sources (*e.g.*, embryonic stem cells (ESC), iPSCs and organ-specific cells as adult stem cells (ASCs))^{50,53–56} that can be obtained from tissue biopsies.⁵⁷ Besides stem cell-derived cells, also cancer cell lines (*e.g.*, HepG2, HepaRG, HUH7, primary liver cancer cells (PLC)) are generally used as cell sources for the development of liver organoids.^{52,58–61}

Organoid formation protocols have been mainly developed from principles in organogenesis. To achieve self-organization, it is essential that organoids should be treated with appropriate biochemical (in liver organoids, *e.g.*, growth factors/glucose addition) and biophysical (*e.g.*, matrix stiffness, mechanical properties) stimuli to promote maturation, tissue-specific or disease-specific differentiation. More specifically, organoid culture media must contain growth factor such as R-spondins (Rspo1) to promote organoid formation as well as Noggin (NOG) and bone morphogenetic protein (BMP) signaling antagonists to either inhibit or prevent other tissue-specific differentiations cues (*e.g.*, mineralization).^{62,63} Parallely, ascertained medium glucose levels have to be utilized to control cellular proliferation, investigate drug, and hepatic metabolism outcomes, as well as glucose production.^{64–66} Moreover, specific interactions among cell populations and biophysical environment should also be strictly controlled to recapitulate heterogeneous structures like the liver tissue.^{67,68} Organoids can be formed *via* 3D suspension culture systems (*i.e.*, using ultra-low attachment plates), spinning bioreactors, air-liquid interface methods, and extracellular matrix (ECM)-based embedding matrices (*e.g.*, Matrigel). Also, combinations of different methods may enhance the organoid formation and boost tissue-specific functions.⁶⁹ For instance, ECM embedded organoids can be used as a scaffolding material, and bioreactors may be employed to improve nutrient absorption.⁷⁰

One of the first attempts that demonstrated the successful generation of a functional human liver organoid from pluripotent stem cells was reported by Takebe *et al.*, who obtained a vascularized functional human liver from iPSCs upon transplantation of liver buds.⁷¹ More recently, Akbari *et al.* obtained *in vitro* differentiation of endoderm-derived hepatic organoids into functional hepatocytes using a human-derived iPSC organoid culture system, producing both healthy and disease models from healthy human donors and citrullinemia patients, respectively.⁷² These liver organoid models were then further investigated to model the urea cycle disorder referred to as citrullinemia type 1 (CTLN1), a disease caused by a mutation in the argininosuccinate synthetase 1 (ASS1) gene causing ammonia accumulation in the blood. The authors modeled CTLN1, using EpCAM⁺ (Epithelial Cell Adhesion Molecule positive) endodermal cells as an intermediate, thus generating functional pathologic hepatic organoids (eHEPOs) that exhibited epithelial morphology and a pseudostratified structure (Fig. 3B).⁷² Moreover, this study indicated that


eHEPOs were suitable to be expanded for more than six months without any significant loss in their phenotypic characteristics and proliferation rate, confirming the pluripotency of citrullinemia patient-derived iPSCs.⁷² Disease-related ammonia accumulation and ASS1-enzyme related over-expression were detected in CTLN1 patient organoids compared to healthy eHEPOs, thus recapitulating the urea cycle-related disease phenotype in the hepatic organoids. Human iPSCs have also been manipulated to generate heterogeneous functional liver organoids for modeling infectious diseases such as hepatitis B virus (HBV), which may cause life-threatening liver infections.^{73,74} Nie *et al.*, investigated the host-HBV interactions causing hepatic dysfunction. The outcomes of the study were correlated to the patient-specific genetic background to develop a promising tool for personalized hepatitis treatment.⁷³

Also, organoid platforms have been used to model alcoholic liver diseases (ALD), a CLD caused by an excess of alcohol in the liver. An interesting ALD-model was obtained using hESC-derived expandable hepatic organoids, which in turn incorporated human fetal liver mesenchymal cells (hFLMCs) to mimic ALD-related pathogenesis (*e.g.*, liver inflammation).⁵⁰ An ethanol (EtOH) treatment was assessed to recapitulate the ALD mechanism successfully. Upon optimization, the EtOH-treated hepatic organoids showed increased pro-inflammatory signaling of interleukins-1 (IL-1) and interleukins-17 (IL-17) compared to untreated control organoids, as well as fibrosis and ECM accumulation. Recently, ALD-related fatty liver diseases such as steatohepatitis have also been modeled with organoid cultures to recapitulate the pathology progression and potentially use of the developed platform for drug screening purposes.⁴⁷ Multi-cellular human liver organoids (HLOs) were generated using 11 different types of healthy and diseased patient-derived iPSCs and hESCs. A free fatty acid exposure was assessed on HLOs *via* oleic acid treatment which significantly induced the progression of the steatohepatitis-like pathology over time (*i.e.*, steatosis, inflammation, and fibrosis), as well as increased organoid stiffness due to the extensive liver fibrosis. Surely, the successful development of such multi-cellular *in vitro* organoid models should be considered relevant for further screening of human liver disease treatments.


Besides iPSCs and hESCs, primary cell-derived organoids have been reported as 3D models that may represent the donor tissue closely.^{75–77} In light of this, Gómez-Mariano *et al.* obtained adult human liver organoids from liver biopsies to model liver disease originating from different mutations of the alpha-1 antitrypsin (AAT) protein, an inhibitor produced by PHH that protects organs from infections and irritation effects.⁷⁶ Such engineered organoids successfully recapitulated the typical features of deficient AAT liver cells. Indeed, results showed typical hypoalbuminemia and lower AAT secretion caused by AAT deficiency, providing a preclinical model for AAT-related liver diseases. Similarly, Nuciforo *et al.* generated long-term human liver tumoroids able to maintain histological features of the originating tumor from hepatocellular carcinoma (HCC) patient needle biopsies, allowing for the *in vitro*




A Healthy liver model




Liver disease model



B



C



D




Fig. 3 Liver organoid-based models. (A) Schematic of organoid formation: in the case of healthy donors, the final organoids can be formed from stem cells, hepatocytes, cholangiocytes, endothelial cells, or their combination; in the case of pathologic cells (affected by tumor, hepatitis, etc.), the organoids represent a liver disease model formed from pathological or cancer liver cells. (B) Bright-field images of hepatic organoid growth at different culture passages (P). Reproduced with permission.⁷² Copyright 2019, The Authors, published by Elsevier. (C) Representative tissue biopsies of tumor and healthy liver used to form organoids. (D) Culture of organoids. Bright-field images of organoids derived from tumor and healthy livers: tumor organoids appear as compact spheroids, while healthy liver organoids show cystic structures. P = passage number; scale bar: 500 μ m. (C and D). Reproduced with permission.⁷⁵ Copyright 2018, The Authors, published by Elsevier.



recapitulation of the cancer growth pattern up to 1 year (Fig. 3C and D).⁷⁵ In the same study, patient-specific sensitivity to sorafenib – a kinase inhibitor drug used to treat HCC – was tested on tumoroids, leading to potentially reduced differences in the efficacy of current clinical HCC treatments among patients and ultimately suggested as a valid tool for tailored therapies.

Over the last decade, liver organoids have been widely investigated also for drug development and screening platforms, toxicity testing tools, as well as for the design of patient-specific therapies.^{78–80} For instance, patient-derived organoids have been described to validate drug studies for specific groups of patients to predict the effectiveness of therapies against drug-induced liver injuries (DILI).⁸¹ Relevant outcomes were shown by Skardal *et al.*, who tested the cytotoxic effect of the chemotherapy medication 5-fluorouracil (5-FU) at different concentrations (*i.e.*, from 0 up to 100 mM) on liver tumoroids for drug screening purposes.⁸² Organoids consisted of cross-linked dextran (Sephadex®) microbeads that were coated with thiol-functionalized hyaluronic acid (HA)/thiol-functionalized gelatin hydrogel blend by using a reduced pressure method, thus obtaining hyaluronic acid-coated microcarriers (HAMs). Subsequently, human colon carcinoma cells HCT-116 Tumor Foci and HepG2 cells were seeded on the HAMs surface to finally generate liver organoids with a rotating wall vessel bioreactor culture system. A 5-FU dose-dependent decrease in the organoid metabolism was revealed within the range 0–10 mM.⁸² Similar to 5-FU, patient-derived organoids treated with sorafenib has also showed a dose-dependent trend on decreased growth of hepatocellular carcinoma cells directly obtained from human tumor needle biopsies.⁷⁵ An interesting study on patient-specific cholangiocyte organoid-laden collagen type-1/Matrigel culture revealed the potential cancer medication effect of VX-770 (*i.e.*, Ivacaftor) on cystic fibrosis (CF) by restoring the CFTR gene, which causes such genetic disorder.⁴⁹ In addition, octreotide – a synthetic analog of somatostatin – was also tested for polycystic liver disease reducing the organoid size, thus revealing its role in reducing the cyst size.⁴⁸

Besides CF and liver tumors, organoids have also been employed to investigate *in vitro* the treatment of DILI. Indeed, DILI is one of the major causes of liver damage worldwide, and it can be classified as direct- and idiosyncratic-drug hepatotoxicity.^{83–85} Direct hepatotoxicity is mostly dose-dependent; on the other side, drug sensitivity reactions may lead to idiosyncratic reactions. Herein, various studies have been designed to assess the hepatic toxicity of medical drugs.^{86–89} Standard evaluation methods include the measurement of hepatic enzyme activity and structural changes in hepatocytes. An interesting study by Au *et al.* proposed a microfluidic drug screening platform for collagen type 1-based liver organoids treated with dexamethasone (*i.e.*, CYP3A4 inducer) and ketoconazole (*i.e.*, CYP3A4 inhibitor) to assess the model's drug metabolism.⁸⁸ Liver organoids were formed in the custom-made device by co-culturing HepG2 and NIH 3T3 fibroblast cells embedded in the hydrogel

matrix. Given that the organoid volume has decreased enabling cell–cell interaction and tissue functionalities due to higher and native-like cell densities in a reduced volume, a contractility test was performed.⁹⁰ Results showed that the presence of the fibroblasts may reduce the volume of the organoid over 4 days, compared to sole HepG2-organoids. Likewise, albumin secretion after 4 days was significantly higher in co-culture organoids than in HepG2 mono-culture 3D structures, thus showing the role of fibroblasts in the improved functional activity of HepG2 hepatocytes and organoid densification. Additionally, the 3T3-HepG2 co-culture organoids treated with dexamethasone exhibited higher CYP activity and metabolism, while ketoconazole-treated organoids revealed a lower metabolism as expected from the chemical inducer and inhibitor treatment, respectively. Similar studies on CYP activity and organoid microstructure have been modeled using common drugs such as acetaminophen (APAP) and troglitazone on Matrigel-based 3D cultures.^{54,86,87} For instance, Ramli *et al.* developed hepatic organoids that closely mimicked the 3D interaction of two different human liver cell types (*i.e.*, hepatocytes and cholangiocytes) to engineer an organized functional bile canaliculi system.⁵⁴ A drug-induced cholestasis was modeled by incubating the organoids in troglitazone for different time periods, showing their role in the loss of the bile canaliculi system. Both hepatocyte and cholangiocyte functionalities were confirmed from the increased CYP450 activity expressed over the differentiation time and the alkaline phosphatase (biliary) activity, respectively; thus, suggesting that the model can be used to explore and further study liver cholestasis.

Alongside disease models, liver organoids in microfluidic systems have also gained attention for the possibility of developing large-scale high-throughput toxicity- and drug testing platforms.⁹¹ In a study proposed by Shinozawa *et al.*, a robust protocol to form human iPSC (hiPSC)-based liver organoids for the preclinical identification of DILI has been developed and tested for 238 active components of commercially available drugs including antibiotics (erythromycin), chemotherapy agents (floxuridine), antivirals (Ritonavir), and anti-inflammatory drugs (nimesulide).⁸¹ Similarly, on a smaller scale, vascularized ECM-based human pluripotent stem cell-derived liver organoids have also been utilized for high-fidelity screening of different marketed drugs based on cholestatic and mitochondrial toxicity.⁸⁰

Ultimately, the most significant advantage of the organoids is that they are the only 3D *in vitro* models that can be cryopreserved, presenting promising opportunities for specifically biobanking applications.^{92–95} Especially, cryopreservation of human ESC (hESC)-derived organoids hold great attention of biotech companies for pharmaceutical purposes. Despite ethical concerns on both research and therapeutic use of hESC organoids, their unlimited capability for self-renewal as well as the potential to differentiate into different tissues make them unique tools for personalized therapies to model liver diseases such as CF,⁴⁹ ALD,^{47,50} and injuries,⁵⁰ together with toxicity prediction purposes.^{86,92–95}



3. Liver-on-a-chip platforms

Organ-on-a-chip platforms have been developed to scale single organ or tissue-specific functions down to the chip format.⁹⁶ Typically, such platforms range from millimeters to centimeters in size and are characterized by microfluidic channels that guarantee a versatile manipulation of small amounts of fluids at the micro-scale. Thus, these tools provide a precise control over the flow regimes and an accurate timing-control of chemical reactions that the user may trigger.⁹⁷ Herein, microchannels can reproduce *in vivo* tissue-specific cell densities by manipulating media-to-cell volume ratio.^{98,99} Moreover, the number of cells required to develop these models is significantly lower than that of macroscale systems (e.g., 3D scaffold-based models). Such a feature may be a critical advantage considering the limited availability and low proliferative character of primary hepatocyte cultures. However, the number of cells required is still a critical parameter which has to be carefully selected considering the dimension of the microfluidic platform.

Among others, cell patterning is one of the most pioneering techniques in fabricating liver-on-a-chip platforms, as it enables appropriate positioning of the different cell populations in complex designed systems, including Liver Acinus MicroPhysiology System (LAMPS), Tapered Stencil for Cluster Culture (TASCL), and OrganoPlate® (Fig. 4A). In one work by Ho *et al.*, hepatic-like lobule arrays have been designed to recreate the lobule pattern, allowing for the precise positioning of two different cell lines (*i.e.*, human liver cancer cell line (e.g., HepG2) and human umbilical vein endothelial cells (HUVEC)).¹⁰⁰ In such a system, an organized cell distribution with appropriate morphology was obtained by increasing liver-specific enzymatic activity.

Similarly to other 3D *in vitro* models, liver-on-a-chip platforms provide a suitable microenvironment allowing for mimicking cell–cell interaction and in turn maintaining of cell morphology and polarization.¹⁰¹ Moreover, liver-on-a-chip platforms enable the study of both static and dynamic cell culture conditions. Although static cell cultures have been successfully employed in pre-clinical disease modeling and drug development studies, *in vitro* perfused cell culture systems are characterized by a more biomimetic condition (Fig. 4B and C).¹⁰² In fact, static culture systems may limit the nutrient supply and accumulate waste, likely inducing hepatocyte dedifferentiation and decreasing liver-specific functions.¹⁰³ On the other hand, perfusable systems can provide continuous transfer of nutrients and metabolites to finally mimic the multiple cell–cell interactions of the liver sinusoidal structure.^{104,105} Furthermore, dynamic culture conditions allow for the creation of a stable oxygen gradient, thus replicating the peculiar metabolic zonation of the liver.^{28,106–109} For these attractive features, research on liver-on-a-chip platforms has gained enormous attention in recent years, and various strategies have been established.

For instance, Lee *et al.* designed a biologically inspired artificial liver sinusoid in a microfluidic chip that mimics the liver

endothelial barrier layer. A collar region of parallel microchannels ($2\ \mu\text{m} \times 1\ \mu\text{m}$, width $\times$ height) was designed to reproduce the endothelial-like barrier, which in turn surrounds a main cell inlet channel. A sinusoid-like flow channel was patterned at the frame of the chip, thus allowing for hepatic microcirculation. Herein, different mass transport parameters (e.g., channel length, height and width, fluidic resistance, volumetric flow rate, Reynolds number) were set.¹¹⁰ In the middle of the device, a cell culture area was placed. Primary rat and human hepatocytes (PRH and PHH, respectively) were loaded into the cell culture area. At the same time, the microfluidic platform was continuously perfused with culture medium in a standard incubator. Since the barrier channels had a cross-section much smaller than the cell diameter, hepatocyte packing was enabled without causing membrane damage. Moreover, due to the small scale of the device, continuous nutrient exchange was possible through simple diffusion, and extensive cell–cell interactions were allowed. In light of this, such culture conditions promoted high hepatocyte viability (>90%) for over 7 days of culture.

Another advanced perfusable 3D *in vitro* liver chip was developed to model Non-Alcoholic Fatty Liver Disease (NAFLD) by encapsulating sacrificial thermoresponsive poly(*N*-isopropyl acrylamide) (pNIPAAm) fibers into enzyme-crosslinked spheroid-laden gelatin hydrogels.¹¹¹ The fibers were then dissolved away from the hydrogel with medium perfusion below the gel-sol transition temperature (*i.e.*, 32 °C) to obtain hollow channels mimicking the liver microvasculature, thus generating an interconnected network of microchannels with physiologically relevant capillary-like diameters (*i.e.*, $17.78 \pm 8.73\ \mu\text{m}$ on average). Liver cell spheroids were prepared using a monoculture of normal mouse liver hepatocytes and a hepatocytes/endothelial cells/HSC tri-culture. Here, the perfused system promoted the lipid metabolic activity of hepatocytes. Also, hollow gelatin-based channels with perfusion revealed higher albumin and CYP3A4 expression over 10 days of culture than non-perfused groups, confirming the role of micro-vascularization in liver maintenance. Afterward, NAFLD was modeled in its early inflammatory and late fibrosis stages (*i.e.*, nonalcoholic steatohepatitis (NASH)) on the liver-on-a-chip platform upon palmitic acid treatment, a fatty acid that may induce reactive oxygen species (ROS)-mediated apoptosis in a dose-dependent manner. Results showed that a 10-day treatment led to intracellular ROS accumulation and increased inflammatory markers expression (interleukins-6 (IL-6) and Tumour Necrosis Factor α (TNF α)), thus successfully replicating inflammation, lipid accumulation, and fibrosis occurring during the progressive processes of NAFLD.¹¹¹ Another study successfully developed a microfluidic chip to model NAFLD progression using different free fatty acid gradients to perfuse primary hepatocytes. Moreover, such a microfluidic platform was used to create oxygen-driven steatosis zonation to investigate the role of oxygen deprivation in hepatocyte lipid accumulation. The model successfully mimicked the sinusoidal lipid distribution on a single continuous tissue and ultimately showed that such fat zonation disappears under progressed steatosis.¹¹²






Fig. 4 Liver-on-a-chip platforms. (A) Different cell sources, such as stem cells, endothelial cells, and liver-derived cells (e.g., healthy and pathological parenchymal and non-parenchymal cells) can be introduced into a microfluidic chip to obtain liver-on-a-chip models. The microfluidic devices, including LAMPS (i), TASCL (ii), and OrganoPlate® (iii), can be employed for disease modeling or drug testing purposes. (i) Reproduced with permission.¹¹⁵ Copyright 2017, SAGE. (ii) Reproduced under the terms of the Creative Commons Attribution 4.0 International License (<https://creativecommons.org/licenses/by/4.0/>).¹¹⁸ Copyright 2015, published by SAGE. (iii) Reproduced under the terms of the Creative Commons Attribution 4.0 International License (<https://creativecommons.org/licenses/by/4.0/>).¹²⁰ Copyright 2021, The Authors, published by Elsevier. (B and C) Evaluation of hepatocyte spheroid response into the chip: (B) cell morphology observed in phase contrast micrographs up to 24 days of culture; (C) cell viability evaluated via live/dead staining at day 24 of culture. Scale bar: 100 μ m. Reproduced under the terms of the Creative Commons Attribution 4.0 International License (<https://creativecommons.org/licenses/by/4.0/>).¹⁰² Copyright 2017, The Authors, published by Springer Nature. (D) Fluorescent images of 3-cell type liver-on-a-chip: organ and perfusion channels are seeded with pluripotent stem cell-derived hepatocytes (iHep) clusters and endothelial (HMEC-1) cells/Kupffer (THP-1) cells, respectively. Cells are stained with nuclei/F-actin/CD68 in blue/red/yellow colors. (E) 3D reconstruction of the perfusion channel. (D and E) Reproduced under the terms of the Creative Commons Attribution 4.0 International License (<https://creativecommons.org/licenses/by/4.0/>).¹²⁰ Copyright 2021, The Authors, published by Elsevier.



To boost the mimicking of *in vitro* hepatic microenvironment, liver-on-a-chip platforms can also be employed to real-time monitor parameters such as oxygen gradients and the expression of metabolic enzymes.¹⁰⁸ Sato *et al.* monitored the cellular oxygen consumption rate of hepatocytes in a microfluidic device that can simultaneously expose cell layers to areas with different oxygen concentrations (*i.e.*, area 1 – hyperoxia, areas 2/3 – physiological conditions, area 4 – hypoxia) and automatic medium exchange for long-term culture.¹¹³ The measurement of partial oxygen pressure was performed *via* a laser-assisted phosphorescence quenching method. The *in vitro* zone-specific mRNA expression of metabolic genes such as phosphoenolpyruvate carboxykinase (PEPCK) and glucokinase (GK) increased in the periportal and pericentral regions (*i.e.*, areas 2/3) as in *in vivo* condition. Moya *et al.* used a microfluidic layer-by-layer device integrated with oxygen sensors to attain the real-time metabolic activity of the liver system.¹¹⁴ Similarly, Lee-Montiel *et al.* developed a microfluidic platform (*i.e.*, LAMPS, Fig. 4A(i)).^{115,116} The LAMPS model was constructed in a microfluidic chamber (50 μ l volume) to recapitulate the liver acinus structure and multiple zone-specific functions by recreating liver Zone 1 and Zone 3 oxygen microenvironments. The microfluidic chamber incorporated sequential cell layers composed of primary human endothelial cells, hepatocytes, and HUVECs, as well as human monocyte cells (Kupffer-like immune cells), LX-2, and immortalized human hepatic stellate cells (HSCs), where the structural organization of the model was improved by depositing a thin layer of porcine liver ECM between the hepatocytes and the endothelial cells to mimic the space of Disse.¹¹⁶ Finally, specific *in vitro* liver oxygen zonation was achieved by perfusing LAMPS at both 15 μ l h⁻¹ and 5 μ l h⁻¹ to recreate Zone 1 and Zone 3, respectively. These values were calculated *via* a computational model of oxygen flows directly installed into the device, thus considering media transport, material permeability, and cellular consumption. As a result, zonation-dependent lipogenesis (*i.e.*, steatosis) showed that LAMPS could be used to model and investigate zone-specific liver metabolism and diseases, as Zone 3 was found to consistently possess higher lipid-filled cells than those located in Zone 1.¹¹⁵

Microfluidic platform features can also be exploited to perform liver drug screening and hepatotoxicity studies. For instance, Skardal *et al.* realized a microfluidic platform with four parallel culture chambers to produce multiple and identical liver structures for toxicology testing.¹¹⁷ A HA/gelatin-based hydrogel formulation containing liver cancer cells (HepG2) was mixed in a 1:1 ratio with a Glycosyl/Gelin S/polyethylene glycol diacrylate (PEGDA) pre-polymer formulation (2:1:1 ratio) to obtain a hydrogel precursor cell-mixture with the addition of a photo-crosslinkable precursor. The solution was inoculated through separate channels for a localized *in situ* crosslinking. Once the chambers were filled, a photomask was positioned above the microfluidic device to selectively crosslink the structures *via* thiolene reaction. After 7 days of culture, high cell viability was quantified in the liver constructs (>75%). Samples were also tested upon EtOH treatment at

different concentrations (0 mM–500 mM) to evaluate the constructs' functionality and toxicity effects. A dose-dependent behavior was found, as albumin and urea secretion significantly decreased with the increase of EtOH concentration and exposure, suggesting the platform as a potential tool for drug development and toxicology screening.¹¹⁷

Similarly, a patterned toxicity evaluation system was developed to simultaneously assess different drug screenings in the same microfluidic device (*i.e.*, TASCL, Fig. 4A(ii)).¹¹⁸ The TASCL device was fabricated with an overall size of 10 mm $\times$ 10 mm, in which 400 microwells were designed and patterned with a top and a bottom aperture, measuring 500 μ m $\times$ 500 μ m (square) and 300 μ m in diameter (circular) each, respectively. TASCL was seeded at different cell densities to investigate the formation of HepG2 spheroids. As a result, the microfluidic platform ensured suitable spherical aggregation, high viability, and albumin secretion upon highly precise positioning.

Also, commercial microfluidic platforms can be used for liver drug screening. Among them, OrganoPlate® platforms have been employed for hepatotoxicity studies (Fig. 4A(iii)).^{119,120} Such a device contains a specific number of microfluidic tissue culture chambers (*e.g.*, 40, 64, or 96, according to the model) designed and embedded on the bottom of a commercial 364-well plate. Each culture chamber consists of one culture channel containing an ECM-based hydrogel of choice and up to two adjacent perfusion channels separated by specific phase guides to prevent the patterned hydrogel from flowing into the adjacent channels. Moreover, OrganoPlate® platforms are stimulated by a gravity-driven leveling technology that enables the induction of a continuous passive perfusion flow without using an external pump or tubing line. Thus, such microfluidic platforms allow for the separation of the cell culture area and the perfusion flow without any physical barrier, as well as indirect contact between the cells and the flow due to the polymerization of the hydrogel matrix. In particular, Bircsak *et al.* developed a liver-on-a-chip platform for high throughput hepatotoxicity screening, using an OrganoPlate® model with 96 culture chambers with two separate channels (*i.e.*, one perfusable and one containing an ECM-based hydrogel).¹²⁰ Specifically, hiPSC-derived hepatocytes (iHep) were seeded in the ECM channel and co-cultured with endothelial cells and THP-1 monoblasts differentiated to macrophages seeded in the perfusable channel. Such multicellular microfluidic structure allowed the formation of iHep clusters in the ECM-channel and a 3D tubular endothelial layer structure in the perfusable channel (Fig. 4D and E). After 15 days of culture, cells were viable and exhibited stable albumin and urea secretion. Moreover, an increase in the CYP3A4 activity and the decreased alpha-fetoprotein (AFP) secretion suggested further maturation of the iHeps. In addition, troglitazone and a small library of 159 compounds with known liver effects have been employed to successfully validate the device as a platform for liver drug testing.

Furthermore, different biomaterials such as ECM components and naturally derived hydrogels can be integrated into liver-on-a-chip platforms to enhance their biomimetic poten-



tial.¹¹⁹ The addition of a 3D *in vivo*-like tissue microenvironment can be beneficial for cell maturation. Hence, a 3D architecture can provide suitable physicochemical properties to mimic physiologically relevant conditions (*i.e.*, cell–cell interaction and metabolic pathways). Although ECM-derived materials possess fast degradation rates and lack robust mechanical properties, components such as Matrigel, collagen, and fibronectin (FN) have been widely employed,^{115,121–123} as well as decellularized liver matrices,^{115,124} gelatin-based hydrogels,¹¹¹ and hybrid formulations.¹²⁵ For instance, Toh *et al.* performed a collagen-coating on a multiplexed microfluidic hepatocyte culture system, allowing for the investigation of the metabolic functions of hepatocytes.¹²⁶ Furthermore, the liver chip was used to predict *in vivo* hepatotoxicity testing for five different drugs in an *in vitro* dose-dependent manner (*i.e.*, acetaminophen, diclofenac, quinidine, rifampin, and ketoconazole). Also, the integration of liver decellularized ECM (dECM) and gelatin methacryloyl (GelMA) in a dynamic microfluidic-based 3D cell culture system displayed a linear dose-dependent drug response to the toxicity of Acetaminophen and sorafenib.¹²⁵

In conclusion, coupling liver-on-a-chip technologies with perfusion-based systems can be beneficial for the development of 3D *in vitro* models that aim to functionally recapitulate the liver microarchitecture and realize robust platforms for high-throughput screening of hepatic diseases and drug compounds.

4. 3D liver scaffolds

Scaffolds are 3D structures designed to recapitulate the ECM role and provide a proper architecture for cell adhesion and maturation. 3D scaffolding approaches for engineering 3D hepatic tissues rely on cultivating cells within biodegradable scaffolds, either natural, synthetic, or hybrid. Given that scaffolding techniques allow superior control over cell morphology and spatial arrangement compared to organoids and 2D systems, such biofabrication methods can be easily used to model diseases, quantitatively evaluate cytotoxicity, and in turn, assess drug treatments. However, large-scale production and flow control of these constructs to mimic liver vascularization is still challenging. Biofabrication approaches such as electrospinning, micropatterning, casting, and 3D (bio)printing have been strategically exploited as 3D scaffolding approaches for LTE.^{127,128} Among others, biodegradable polymers such as polyethylene glycol (PEG), polycaprolactone (PCL), polylactic acid (PLA), poly-L-lactic acid (PLLA), poly-DL-lactide-co-glycolide (PLGA), polyvinyl alcohol (PVA), and thermoplastic biodegradable polyurethane (PU) polymers have been employed in the frame of LTE.^{129–134} These synthetic polymer-based scaffolds can provide structural support and allow the diffusion of nutrients, oxygen, and cell growth factors without being affected by possible animal-derived pathogenicity and batch-to-batch variability characterizing natural-based polymers.¹³⁵ However, biocompatibility and ECM complexity still remain challenging to recapitulate. To

address this issue, hybrid and/or natural polymer-based biomaterials can be used to fabricate liver scaffolds.¹³⁶ Essential ECM components (*e.g.*, hyaluronic acid, collagen, and FN) can be included in the hydrogel-based scaffolds to better replicate *in vivo* conditions, thus improving the cell–biomaterial interactions. The most common approach to fabricate *in vitro* liver models is based on the use of hydrogels that can mimic and resemble the complexity of the ECM microenvironment, induce and support cell adhesion, proliferation, and differentiation by providing chemical and physical signals. Among others, naturally derived hydrogels such as chitosan, alginate,^{137,138} gelatin,^{139–141} collagen,^{140,141} as well as blend formulations as gelatin/alginate/fibrinogen,¹⁴² and gelatin/alginate¹⁴³ have been extensively explored.¹⁴⁴ Natural materials are overall considered promising candidates for developing engineered liver tissues for selecting and fastening drug candidates. GelMA- and fibrin-based hydrogels have been used not only for the hierarchical vascularization of liver constructs (*e.g.*, lobule-like microstructures, spheroids, fibers), but also for hepatocyte differentiation^{145–149} and drug screening.^{109,150} Given the soft nature and rapid degradation of most hydrogels, a crosslinking process (*e.g.*, photo-mediated for GelMA, ionic for alginate) or a supporting framework made of synthetic biomaterials (*e.g.*, PCL) is required to reach the structural integrity of the constructs for *in vitro* testing.^{151–154} Beyond these widely explored hydrogel-based formulations, the combination of different techniques and hybrid hydrogel biomaterials allowed to highlight the power of LTE multidisciplinary area to mimic the native complexity of the liver and investigate its pathogenic microarchitecture. Also, unpopular cell-based applications can be functionalized by coating the material surface with hydrogel-based formulations. For example, it was shown that paper may enhance the hepatic function of *in vitro* 3D liver models in the presence of human-induced hepatocytes (hiHEPs) and HUVECs co-culture upon Type I collagen.¹⁵⁵

In this section, a discussion of the most thought-provoking advances in 3D liver models obtained by 3D scaffolding strategies is provided. In light of this, biofabrication techniques such as 3D printing, 3D bioprinting, and electrospinning for *in vitro* disease modeling and drug testing are thoroughly described. Due to the limited possibility of developing controllable and complex architectures for physiologically relevant structures, more conventional methods like molding, extrusion, and micropatterning are out of the scope of this review.

4.1. 3D printed scaffolds

3D printing technology has been considered an emerging strategy to fabricate tailored structures for tissue engineering relying on the layer-by-layer deposition of biomaterial inks. A 3D CAD design that reproduces the scaffold complex architecture is subsequently converted into a code to produce a 3D construct with the desired geometry.¹⁵⁶ Reproducibility, high control over the process and the scaffold size are considered the main advantages of this 3D deposition processing method.^{157,158} In LTE, the extrusion-based 3D printing approach allows for shaping constructs that can recapitulate



the characteristic repetitive liver microstructure (e.g., lobule architecture). However, biomaterial characterization and scaffold geometry are currently gaining more attention over liver functionality outcomes, as LTE is a new trend in the field.¹⁵⁹ In addition, costs, resolution, and lack of high throughput are potential limitations in the frame of liver disease modeling and drug testing. Typically, 3D printed engineered constructs with potential applications in human disease modeling have been investigated focusing on different geometries, pore size, and gene expression, revealing increased specific functions in more interconnected 3D printed scaffolds able to mimic the complex liver architecture.^{105,160–163} Based on the pore tortuosity influence on seeding efficiency,¹⁶⁴ Lewis *et al.* showed that different pore geometry could positively modulate hepatocyte function and gene expression. They found that HUH-7 cells might improve CYP activity and bile transport upon seeding on 3D-printed gelatin scaffolds.¹⁶¹ Two different gelatin-based geometries were explored, with a strut orientation between subsequent layers of 90° or 60° of square boxes. Changes in the scaffold geometry were found to be responsible for gene expression over cell numbers. Indeed, scaffold architecture may significantly affect hepatocyte function, as shown by the higher activity of CYP3A4 and CYP2C9 in 60° geometry scaffolds, which also confirmed the higher formation of canalicular spaces. Different strategies to fabricate 3D perfused constructs have lately focused on highly porous structures. Indeed, interconnected pores allow cell growth and mass transport.^{30,165,166}

3D printed architectures have also been developed to evaluate the influence of 3D porous structures and dynamic mass transport on drug testing platforms.^{74,105} Vinci *et al.* proposed an interesting scalable *in vitro* liver model investigated in terms of 3D topology and convective flow, two primary cues influencing hepatocytes' function.¹⁰⁵ Synthetic materials such as PLGA and PLLA were used to prepare liver constructs employing a pressure-assisted microsyringe (PAM). The 3D scaffolds mimicked the characteristic size of hepatic lobules with three different layers, composed of 70 hexagonal unit cell structures each, thus creating an overall construct with high porosity suitable for cell penetration and adhesion. The authors showed that the 3D porous architecture increased cell density and promoted the formation of aggregates compared to 2D films, thus maximizing cell–cell interactions. Another novel bio-inspired 3D printed construct based on a PEG hydrogel was embedded with polydiacetylene (PDA) nanoparticles to fabricate a detoxification model that may provide an alternative strategy to drug intoxication.¹⁶⁷ Herein, PDA nanoparticles showed their potential in neutralizing melittin toxins *in vitro*. Mimicking the liver lobule-like configuration, the platform was able to attract, catch and sense the melittin toxins, a harmful poisonous substance to humans that can result from animal bites and bacteria.

4.2. 3D bioprinted scaffolds

Similar to 3D printing technology, 3D bioprinting methods rely on computer-assisted layer-by-layer deposition strategies

for the fabrication of clinically relevant constructs.^{168,169} However, 3D bioprinting offers the potential to encapsulate cells inside biomaterial inks, thus enhancing the biomimetic features towards the reproduction of a more realistic physiological and pathological liver microenvironment.^{18,170,171} Such cell-laden solutions (*i.e.*, bioinks) are mainly based on hydrogels. Contrarily to other biomaterials, hydrogels possess unique properties, such as high water content and suitability for cell encapsulation.¹⁴⁴ In addition to printability properties (*i.e.*, viscosity, shear-thinning behavior), the choice of hydrogels is also determined by the ability to support cell viability and guarantee the performance of their physiological function.³² Specifically, hydrogels enriched with cell-binding sites are preferred to recreate a more cell-friendly environment. To this aim, protein hydrogels modified with arginine–glycine–aspartic acid (RGD) peptides (e.g., sodium alginate) or ECM-like hydrogels (e.g., collagen, gelatin, GelMA) are preferably selected.^{172–175} To further enhance the biomimicry potential, the liver ECM can also be employed to develop tissue-specific bioinks with the biochemical complexity of the native tissue. Moreover, hydrogel mechanical properties should be tuned to recreate the desired microenvironment stiffness to favor cell migration and reorganization.¹⁷⁶ Finally, scaffold porosity, which is mainly dependent on hydrogel concentration and degree of crosslinking, must guarantee efficient transport of oxygen, nutrients, metabolites, and drug compounds.¹⁷⁷ Regarding the encapsulated cells, both parenchymal and non-parenchymal cells have been employed. Parenchymal cell sources included hepatoma cell lines (e.g., HepG2, HUH-7, and HepaRG).^{138,178} Alternatively, hiPSCs, hESCs, and human hepatocytes can also be used.^{179–181} On the other side, liver non-parenchymal cells can include Kupffer cells, liver ECs, HSCs, and HUVECs (Fig. 5A).^{179,182} Based on the deposition method, 3D bioprinting approaches can be divided into three main methods: (i) droplet-based bioprinting, (ii) extrusion-based bioprinting, and (iii) light-assisted bioprinting. (i) Droplet-based bioprinting involves the precise dispensing of droplets of bioink through thermal, piezoelectric, and electrohydrodynamic methods.^{170,183} For such 3D bioprinting method, the bioink selection is oriented to cell-laden hydrogels formulation characterized by low viscosity properties. (ii) Extrusion-based bioprinting relies on the deposition of continuous filaments of bioinks to form a 3D construct.¹⁸⁴ By optimizing 3D printing parameters (e.g., temperature, pressure, velocity), a wide range of bioinks can be employed to fabricate high-resolution constructs. (iii) Light-assisted (e.g., UV- or visible-light) 3D bioprinting approach employs the selective curing of photo-crosslinkable bioink contained in a printing reservoir.²⁹ Such a method exhibits a high printing resolution that guarantees the fabrication of sophisticated and complex biomimicking architecture in a high-throughput way.

3D bioprinting techniques have been widely used to develop highly accurate/precise/realistic disease liver models. A high geometrical complexity can be achieved by optimizing bioink formulations and 3D bioprinting parameters. Thus, a






Fig. 5 3D bioprinting methods for the production of 3D liver scaffolds. (A) 3D bioprinting of a hydrogel precursor solution is loaded with parenchymal, non-parenchymal liver-derived cells, cancer cells, stem cells, and/or cell lines. Afterward, the 3D printed construct is crosslinked via different methods (e.g., UV irradiation, crosslinking in a crosslinking bath) to allow the crosslinking of the hydrogel. (B) Advantages of the 3D bioprinting technique.



proper recapitulation of the liver structure similar to *in vivo* pathological conditions can be performed. For example, Wu *et al.* incorporated cellulose nanocrystals (CNCs) into an alginate/GelMA formulation to enhance shear-thinning behavior and shape fidelity upon bioink deposition.^{185,186} Indeed, CNCs were found to align along the printing direction, thus enhancing the bioink extrudability compared to pristine alginate/GelMA bioink. The bioink was extruded directly on a cover glass or in an alginate/calcium chloride (CaCl₂) supporting bath and subsequently crosslinked by UV light exposure. A high-accuracy liver-biomimetic 3D honeycomb structure was successfully produced. Such structure was employed as a 3D platform for co-culturing two different cell types (*i.e.*, NIH 3T3 and HepG2). Specifically, NIH 3T3/Alginate/GelMA/CNCs bioink was deposited to create the lobule-like structure, while HepG2/GelMA was deposited inside the hexagonal holes. The precise positioning of cells allowed for the alignment of NIH 3T3 fibroblasts and the formation of HepG2 spheroids, thus recapitulating the overall 3D biomimetic structure. Moreover, intracellular interactions enhanced albumin secretion compared to HepG2 culture used as a control. Pathological conditions can be reproduced by mimicking intracellular events and cross-talks. To this aim, 3D bioprinting enables the fabrication of biomimetic microenvironment hosting multiple cell types.¹⁸⁷ For instance, Cuvelier *et al.* established a tri-culture model consisting of HepaRG/LX-2/HUVECs to recapitulate the progressive development of fibrosis *in vivo*.¹⁸⁸ HepaRG/LX-2 were mixed with GelMA and 3D bioprinted in a square-shaped construct. Afterwards, scaffolds were crosslinked by UV-photopolymerization. HUVECs were seeded after one week of culture to recreate a pseudo-endothelial barrier following colonization of the surface structure. The 3D bioprinted structures exhibited long-term viability, proliferative ability, hepatocyte phenotype and functions. Moreover, the 3D bioprinted model was suitable for the interaction between parenchymal and non-parenchymal cells, which was modulated by the secretion of TGFβ-1 that in turn induced the activation of myofibroblastic genes (*i.e.*, ACTA2 and COL1A1). As a result, a fibrillar collagen synthesis deposition was observed, which was not evidenced in monocultures of either HepaRG or LX-2.

Besides single-cell dispersion, 3D bioprinting was found to be suitable also for the encapsulation of 3D spheroids. Goulart *et al.* performed a study to compare 3D bioprinting of iPSC-derived hepatocyte-like spheroids and single cell dispersion, both in combination with iPSC-derived mesenchymal cells and ECs in alginate/Pluronic F-127 blend bioink formulation.¹⁸⁰ 3D hepatic spheroids were successfully 3D printed in a donut-shaped geometry construct and cross-linked with CaCl₂ upon biofabrication. After 18 days of culture, the viability of the cultured spheroids was significantly higher than single cells. Moreover, 3D spheroids exhibited higher expression of liver-specific markers, including increased urea production and prolonged secretion of albumin. In addition, single cells revealed epithelial-mesenchymal transition, resulting in a rapid loss of hepato-

cyte phenotype. By tuning 3D printing parameters, constructs with tunable mechanical properties can be obtained. In particular, light-assisted 3D bioprinting technologies offer the possibility to modulate the photo-polymerization processes, thus allowing for the fabrication of constructs with regionally different mechanical properties. Such interesting feature provides a valuable tool for fabricating platforms that aim to replicate liver pathologic conditions (*e.g.*, cirrhotic liver) characterized by higher mechanical properties than the native liver tissue in physiological conditions. Ma *et al.* used light-assisted 3D bioprinting to pattern a photo-crosslinkable GelMA/dECM formulation with tunable mechanical properties as a platform for studying the effects of stiffness on HCC progression.¹⁸⁹ HepG2 cells were encapsulated in a lobule-like hexagonal structure with different mechanical properties to recapitulate both the native and cirrhotic liver tissue. For scaffolds with lower stiffness, cellular aggregation and spheroid formation were observed with increasing spheroid size during the culture period. Contrarily, reduced growth was observed for HepG2 cells cultured in scaffold with cirrhotic mechanical properties. Moreover, stiffer scaffolds showed an upregulation of invasion markers (*i.e.*, insulin-like growth factor 2 (IGF-2)) compared to physiological native-like controls. To further investigate the HepG2 invasion potential, a biomimetic design consisting of three hexagonal lobules, each possessing different stiffness (*e.g.*, soft, medium, and stiff scaffolds), was developed. Each hexagonal unit was interconnected with a collagen I-based scaffold to recapitulate the fibrous septa-like structure found in the native liver architecture. Such engineered cancer platform enabled the validation of the highest degree of invasion of HepG2 cultured in a cirrhotic mechanical environment into the surrounding stromal region.

The potential of 3D bioprinting in replicating highly biomimetic constructs has been used to produce liver platforms for drug testing purposes (Fig. 5B). Ma *et al.* employed a light-based 3D bioprinting system to produce a UV-cross-linked GelMA-based platform, aiming to embed hiPSC-derived hepatic cells and endothelial- and mesenchymal-originated supporting cells (*i.e.*, HUVECs and adipose-derived stem cells) in a high-resolution hexagonal geometrical pattern that closely mimicked the *in vivo* hepatic lobule structure.¹⁹⁰ The hydrogel-based triculture model promoted cell organization and alignment within the biomimetic architecture. Moreover, higher expression of hepatic markers (*i.e.*, HNF4a, TTR, and albumin) and metabolic product secretion was observed, compared to the 2DMC and the 3D hepatic progenitor cells (HPC) monoculture model. In another study, Sun *et al.* used extrusion-based bioprinting to fabricate a 3D liver cancer model composed of HepG2 suspended in gelatin/alginate. Upon fabrication, the 3D-bioprinted scaffolds were crosslinked with CaCl₂ solution, finalizing the 3D model for liver cancer.¹³⁸ Compared to the 2D model counterpart, HepG2-laden 3D scaffolds showed higher expression of tumor related genes including ALB, AFP, CD133, EpCAM, and TGFβ-1 genes. To validate the cancer model, the anti-tumor



response to several drug treatments (*i.e.*, cisplatin, sorafenib, regorafenib) was evaluated. As a result, it was observed that the half-maximal inhibitory concentration (IC_{50}) values of the tested drugs were higher in the HepG2-laden scaffold model compared to the 2D model. Such findings suggested a higher sensibility of the 2D model compared to the 3D scaffold. However, the IC_{50} values obtained in the 3D-HepG2 model were closer to the effective blood concentration of the drugs in the human body. These outcomes were explained by the higher levels of drug resistance autophagy-related genes (*e.g.*, ABCB1, MDR-1, MRP1, and EGFR) expressed in the 3D-bioprinted model.

The employment of the same 3D printed model was furtherly extended to establish *in vitro* model for patient-specific drug screening for HCC.¹⁹¹ Cells were isolated from HCC-specimens collected from six patients and then combined with gelatin/alginate to produce the bioink. Patient-derived 3D bioprinted scaffolds were successfully fabricated, showing high viability and proliferation rate during long-term culture. Moreover, HCC-scaffolds allowed for retaining the features of the originating HCC tumors, including stable expression of the AFP biomarker, as well as the constant maintenance of genetic alterations and expression profiles. Furthermore, the efficacy of four commonly used empirical targeted drugs for HCC-affected patients was assessed. Most of the HCC-scaffold models derived from the six patients resulted to be insensitive to the four targeted drugs in treatments. However, four patient-specific HCC-derived 3D scaffolds were found to be positively responsive to one or more drugs. For such scaffolds, a dose-dependent manner was observed. For two patients, sorafenib and lenvatinib showed enhanced anti-tumor effects than other drugs, respectively. Such findings encouraged the classification of patient-derived HCC-laden scaffolds as a potential candidate in the field of personalized cancer treatments. 3D bioprinting was also found to be a suitable technology to preserve the differentiation futures of encapsulated cells. For instance, Faulkner-Jones *et al.* performed inkjet-based 3D bioprinting of hepatocyte-like cells (HLCs) differentiated from both hiPSCs and hESCs mixed with RGD/alginate-based hydrogel solution.¹⁷² A cell-laden hydrogel was printed by dispensing an array of droplets of the bioink, followed by an overprinting of droplets of $CaCl_2$ solution to allow the crosslinking. The droplets were dispensed following a circular path, and a ring-shaped structure was finally obtained when adjacent droplets overlapped together and formed a single continuous layer. Upon fabrication, the cell-laden structures continued the differentiation process into hepatocyte-like cells (HLCs) over 24 days of culture. As a result, encapsulated cells were viable and preserved the hepatocyte marker expression validating such 3D printed model as a potential platform for drug testing studies.

4.3. Electrospun scaffolds

Electrospinning is a well-established fiber process employed to produce different interwoven nanofibrous scaffolds with

high porosity, thus closely mimicking the native architecture of soft tissues. In a conventional electrospinning fabrication process, a high-voltage electric field is applied between the tip of a needle and the ground collector, allowing for the spinning solution to initially form a hemisphere drop at the tip of the needle. The surface charge on the polymer droplet increases, allowing for the formation of a polymer jet under an increasing high-voltage power towards the collector.¹⁹² By selecting the proper collector, nanofibers can be deposited to form a fibrous mat characterized by random or preferential fiber arrangement.^{192,193} Herein, electrospinning provides the possibility to tune high porosities and pore size distribution of the engineered constructs reaching a large surface area. Moreover, the features of electrospun fibers at the micro- and nano-scale and the surface roughness may also enable the mimicry of *in vivo* scenarios influencing the adhesion and proliferation rate of the cultured cells in the engineered microenvironment.¹⁹³ Both natural and synthetic polymers can be used to obtain electrospun fibers. Among others, the application of synthetic polymers in this field involves PCL, PLA, and PLGA; while natural-based materials include chitosan and ECM-derived components. In this frame, a combination of different strategies may be applied to functionalize these materials (Fig. 6A). Hence, electrospun functionalized systems have been explored as liver disease models. For instance, Grant *et al.* proposed an electrospun system composed of PLA and human liver ECM (hLECM) components to create a liver disease model. The authors demonstrated that the combination of the synthetic polymer with the hLECM layer properly supports Transformed Human Liver Epithelial-3 (THLE-3) hepatocytes cultured on the surface, showing high cell viability and proper morphology.¹⁹⁵ The possibility of designing drug testing models based on electrospun constructs has also been investigated. Fasolino *et al.* proposed an electrospun fibrous PCL model for hepatocarcinoma treatment by co-culturing two hepatic cell lines (*i.e.*, HepG2, healthy human hepatocytes (HHH)).¹⁹⁴ After 4 weeks, HepG2 cells showed lower proliferation compared to HHH cells. The anticancer effect of PCL on HepG2 was also confirmed by the reduced cell adhesion with respect to culture plates. Then, PCL fibers treated with doxorubicin (DOX) were cultured in the presence of HepG2-only and HepG2/HHH co-culture, respectively; thus, showing lower cell proliferation after 14 days compared to untreated PCL fibers and plate control. Considering that DNA damage induced by ROS production is one of the main mechanisms involved in both mutagenesis and carcinogenesis,¹⁹⁶ the antioxidant effect of co-cultured fibers was also confirmed from the investigation of ROS generation induced by H_2O_2 , a common genotoxic agent. Indeed, PCL fibers concurred to reduce ROS levels at day 1 of culture (*i.e.*, HepG2, HepG2/HHH, healthy hepatocytes), thus validating the scaffold's ability to inhibit cancer development and progression. Drug treatment was similarly investigated by Grant *et al.* with a drug-induced electrospun PCL scaffold by introducing drugs that can inhibit histone deacetylases from enhancing the transcriptional activity, thus modulating the






Fig. 6 3D liver scaffolds fabricated by electrospinning technique. (A) Synthetic polymer(s) are mixed with ECM component(s) in a solution that is electrospun under electric field conditions. The resulting fibrous matrix is then seeded with liver-derived cells and/or cell lines to develop liver disease or drug testing models. Scale bar: 50 mm. (B) Advantages of the electrospinning technique.



cellular response and influencing the ECM production.¹⁹⁷ Electrospun PCL-scaffolds were seeded with 5637 human urinary bladder epithelial cells to produce ECM. To induce a drug treatment, culture medium was supplemented with either Valproic Acid (VA) or Sodium Butyrate (NaB). At the same time, controls were referred to as 3D scaffolds without an initial cell layer and no drug treatment. After 14 days, decellularization was assessed. Finally, the resulting scaffolds were further seeded with HepG2 to allow the constructs to form a functional liver cell layer in standard culture conditions and validate the platform. The drug-induced nanofibrous scaffolds showed a lower adhesion of HepG2 as well as positive effects on the expression of genes related to liver function (*i.e.*, albumin) and metabolism (*i.e.*, CYP450) when compared to controls. Additionally, the expression of key liver ECM proteins (*e.g.*, collagen I, collagen IV, and fibronectin) outperformed in the case of PCL-based nanofibrous electrospun systems in comparison with tissue culture plates. On the other hand, PLGA was also employed to develop ECM-based 3D nanofibrous scaffolds using a wet-electrospinning technique.¹³⁵ Brown *et al.* obtained by wet-electrospinning less dense and highly porous PLGA matrices compared to standard electrospinning technique,^{198,199} thus allowing to replicate the pore size of the acellular parenchyma of the liver and to accommodate the inclusion of human primary hepatocytes (hPHs) in the structures.²⁰⁰ Fibers were spun and collected using a mold soaked in an isopropyl alcohol/de-ionized water solution (7:3 (v/v)). Pluronic® F-108 was used as a surfactant. The scaffolds were then chemically modified with essential liver ECM proteins (type I collagen and FN) to closely mimic the liver microenvironment. Collagen was chosen because it is the major component of the physiological liver ECM, while FN is a critical binding ligand for integrin-mediated cell adhesion. hPHs cultured in both PLGA-ECM and PLGA scaffolds maintained high viability over two weeks. Specifically, hPHs embedded in PLGA-ECM constructs showed higher functionality and exhibited 10-fold greater albumin secretion, 4-fold higher urea synthesis, and elevated transcription of hepatocyte-specific CYP450 genes compared to unmodified PLGA scaffolds. The hepatocyte functionality was also higher comparing collagen to FN-bonded scaffolds. This evidence demonstrated that the incorporation of type I collagen into the biosynthetic wet-electrospun 3D scaffolds improved the hepatocyte functionality *in vitro* and suggested further *in vitro* investigations for pharmacology screening, as well as to preserve hepatocyte function for use in human cell therapy (Fig. 6B). Rajendran *et al.* designed a biomimetic chitosan nanofibrous scaffold fabricated by electrospinning with enhanced porosity, cellular adhesion, and spreading for long-term liver function by coating the surface of randomly oriented chitosan nanofibers with FN.²⁰¹ The seeding of fibroblasts and primary rat hepatocytes revealed the beneficial impact of FN on focal adhesions formation and integrin-binding sites. Also, drug intake and metabolism were confirmed by high levels of CYP450 A1 enzyme activity.

5. Ongoing challenges and future perspectives

To date, impactful advances in *in vitro* LTE have been made to accurately mimic liver-specific functions and predict drug responses (Table 1). Indeed, the recent literature reported a tendency to model liver diseases and assess drug testing by using 3D engineered constructs to closely mimic *in vivo* conditions. Despite such progress, there is an urgent need to extend the research to a large-scale human population to strongly validate *in vivo* the engineered systems. Parallely, this stage could dramatically lower ethical concerns regarding the use of animal models, which may also impair human outcomes. Based on that, human co-culture-based LTE models that can recapitulate *in vivo*-like features would open up the possibility of bridging the gap between laboratory investigation and clinical applications. In Table 1, representative technological approaches and cell sources for *in vitro* 3D liver models are summarized. Moreover, relevant outcomes and major limitations of the proposed 3D liver models are also highlighted to identify the most effective strategy to develop the targeted system. In addition, the main advantages and drawbacks of the previously discussed liver models are summarized in Table 2. Due to their biocompatibility, most of the polymeric materials used are naturally derived. Thus, they are biodegradable and can properly support biological functions and cell growth, offering a suitable biomimetic environment to tailor specific liver architectures. Nevertheless, synthetic polymeric materials may be nondegradable, possess robust mechanical integrity, and maintain high-repeatability geometries. Also, they can be easily tuned to provide low immunogenicity. Although some of them are also used in the clinic, natural hydrogels suffer batch-to-batch consistency and poor mechanical properties, while synthetic polymers mainly lack cell-binding sites. Therefore, either the modification of single-origin materials or the combination of different materials is lately emerging as a new trend to get the most beneficial impact from *in vitro* 3D liver constructs.^{160,202–204} Additionally, to recreate the heterogeneous tissue microenvironment and enable physiological cell–cell interactions, both parenchymal (*e.g.*, primary hepatocytes, hepatic-derived cell lines, stem cells) and non-parenchymal (*e.g.*, Kupffer cells, ECs, HSCs, sinusoidal cells) cell types should be considered according to the final LTE purpose. However, multiple cell populations may require different material properties and network orientations to form characteristic microstructures, leading to a winding research path. For instance, primary hepatocytes are considered the gold standard for hepatotoxicity assessment as they can trigger specific liver functionalities and metabolism features. However, they have limited availability and are not advisable for long-term *in vitro* culture due to their rapid differentiation time.²⁰⁵ Similarly, although liver cancer-derived cell lines (*e.g.*, HepG2, HepaRG) have high proliferation capacity, they could lack metabolic activity such as urea formation, as a result of downregulated enzymatic activities of





Table 1 Summary of representative *in vitro* 3D models for human liver disease and drug screening

<i>In vitro</i> model	Biomaterials	Cell source	Aim of the work	Main outcomes	Limitations	Ref.
Organoids	—	Patient-derived HCC-biopsies	Modeling of human liver cancer derived from tumor needle biopsies	• Long-term cultures • Recapitulation of histological features and tumor markers expression comparable with the originating tumors • Tumor formation with histological features of the original biopsy upon injection of organoids into immunodeficient mice • Dose-dependent trend in response to sorafenib treatment • Metabolically active hepatic organoids	• Reduced number of testing patients • Disadvantages related to liver biopsies (<i>i.e.</i>, patient pain, bleeding, infection, accidental injury to nearby organs)	75
	—	HSC HepaRG	Modeling of drug-induced liver fibrosis	• Collagen secretion and HSC activation after exposure to pro-fibrotic compounds	• Absence of biomaterial providing physico-chemical cues to support cell-growth • Replication of higher biomimetic fibrosis model that could be obtained including Kupffer cells, liver sinusoidal endothelial cells and PHH	60
	HA Gelatin PEGDA	HCT-116 HepG2	Modeling of liver-tumor organoids for tumor growth and drug response	• Enhanced mesenchymal phenotype for cells compared to 2D culture • Dose-dependent behavior resulting from increased apoptosis and decreasing metabolism of HCT-116 with higher concentrations of 5-FU • Automated platform to confine organoids and perform on-chip dilution for hepatotoxicity screening • Enhanced mimicry of fibroblasts contractile behavior and albumin secretion profiles compared to 2D systems • CYP3A4 activities and necrotic/apoptosis consistent with the dose-dependent effect of treatment of chemical inducer/inhibitors on hepatoma cells	• Use of cell seeding over hydrogel cell-encapsulation	82
Liver-on-a-chip	Collagen	HepG2 NIH 3T3	Microfluidic organoid platform for drug screening	• Recapitulation of tumor microenvironment with biochemical factors and biophysical cues • Enhanced hepatocyte viability and functions under flow conditions • Linear dose-dependent drug response to the toxicity of APAP and sorafenib • Successful implantation and maintenance of liver buds in perfusable 3D hydrogels • Realistic replication of inflammation, lipid accumulation, and fibrosis due to the progression of NAFLD compared to animal model • Similar response of liver-on-a-chip model upon the use of hepatic steatosis-reducing drug (<i>i.e.</i>, restoration of mitochondrial activities, reduction of inflammation, oxidative stress, and lipid accumulation) compared to animal model	• HepG2 (cancer cells) prevent the result translation to healthy hepatocytes	88
	GeIMA Decellularized liver matrix	HepG2	Biomimetic liver tumor-on-a-chip model for toxicity testing	• Recapitulation of tumor microenvironment with biochemical factors and biophysical cues • Enhanced hepatocyte viability and functions under flow conditions • Linear dose-dependent drug response to the toxicity of APAP and sorafenib • Successful implantation and maintenance of liver buds in perfusable 3D hydrogels • Realistic replication of inflammation, lipid accumulation, and fibrosis due to the progression of NAFLD compared to animal model • Similar response of liver-on-a-chip model upon the use of hepatic steatosis-reducing drug (<i>i.e.</i>, restoration of mitochondrial activities, reduction of inflammation, oxidative stress, and lipid accumulation) compared to animal model	• Use of animal-derived decellularized liver ECM instead of human-derived ECM	125
	Gelatin pNIPAAm	Mouse liver hepatocytes (AML12) Mouse endothelial cells	Implantable vascularized liver chip for cross-validation of disease treatment with animal model	• Successful implantation and maintenance of liver buds in perfusable 3D hydrogels • Realistic replication of inflammation, lipid accumulation, and fibrosis due to the progression of NAFLD compared to animal model • Similar response of liver-on-a-chip model upon the use of hepatic steatosis-reducing drug (<i>i.e.</i>, restoration of mitochondrial activities, reduction of inflammation, oxidative stress, and lipid accumulation) compared to animal model	• Low reproducibility and control over the fabrication methods to produce hydrogel-based nanofibers for the generation of vessel-like networks	111
		HSCs				



Table 1 (Contd.)

<i>In vitro</i> model	Biomaterials	Cell source	Aim of the work	Main outcomes	Limitations	Ref.
3D printed scaffolds	PLGA	HepG2	Biomimetic 3D scaffold coupled with a modular bioreactor to investigate hepatocyte function	- Increased cell density of seeded culture compared to monolayer controls - Enhanced cell density, formation of aggregates, and gene expressions in 3D scaffolds compared with monolayer controls 3D porous scaffold mimicking the characteristic geometry of hepatic lobules - Increased cell metabolic in dynamic culture in comparison with static monolayer cultures - Precise control over pore geometry and orientation - High viability and proliferation when cells are seeded on 3D-printed scaffolds with different geometries - Enhanced hepatocyte functions (albumin secretion, CYP activity, bile transport) in the interconnected scaffold compared to less interconnected geometries and 2D controls - Successful encapsulation of functional polydiacetylene nanoparticles with detoxification potential - Highly biomimetic 3D scaffold structure enables access to toxins inside the hydrogel matrix - Effective interaction of nanoparticles and toxins - High functionality of nanoparticles enables the toxins capture - Loss of virulence potential in toxin solution after treatment - High printability of high-resolution hexagonal scaffolds without cell damage - Precise positioning of HepG2 and NIH 3T3 bioinks to mimic liver microenvironment - NIH 3T3 alignment at the boundary of the hexagonal lobule - Enhancement of albumin secretion in the bicellular construct compared to NIH 3T3 and HepG2 singles cells culture - Constructs with regionally varied mechanical properties	Low biochemical and biological potential of the 3D printed scaffold	105
	PLLA					
	Gelatin	HUH-7	Modulation of hepatocyte function and gene expression using different pore geometries		Limited 3D scaffold design and architecture complexity	161
3D bioprinted scaffolds	PEGDA	—	Bio-inspired 3D printed scaffold functionalized with nanocomposites hydrogel for detoxification studies	- Successful encapsulation of functional polydiacetylene nanoparticles with detoxification potential - Highly biomimetic 3D scaffold structure enables access to toxins inside the hydrogel matrix - Effective interaction of nanoparticles and toxins - High functionality of nanoparticles enables the toxins capture - Loss of virulence potential in toxin solution after treatment - High printability of high-resolution hexagonal scaffolds without cell damage - Precise positioning of HepG2 and NIH 3T3 bioinks to mimic liver microenvironment - NIH 3T3 alignment at the boundary of the hexagonal lobule - Enhancement of albumin secretion in the bicellular construct compared to NIH 3T3 and HepG2 singles cells culture - Constructs with regionally varied mechanical properties	- High expensive and no commercial 3D printing equipment - Selection of inks limited to photo-crosslinkable hydrogels	167
	Alginate	HepG2 NIH 3T3	Bi-cellular liver biomimetic structure	- High printability of high-resolution hexagonal scaffolds without cell damage - Precise positioning of HepG2 and NIH 3T3 bioinks to mimic liver microenvironment - NIH 3T3 alignment at the boundary of the hexagonal lobule - Enhancement of albumin secretion in the bicellular construct compared to NIH 3T3 and HepG2 singles cells culture - Constructs with regionally varied mechanical properties	Potential cell damage risk due to shear stress induced by extrusion of highly viscous bioinks	186
	Cellulose nanocrystal GelMA					
3D bioprinted scaffolds	Liver decellularized ECM	HepG2	Mimicking of cirrhotic liver environment to predict the HCC development and growth invasion	- HepG2 reduced growth and high degree of stromal invasion from the nodules with cirrhotic-like stiffness compared to healthy controls - Patient-derived scaffolds with high viability and proliferation rate - Good retention of the features of the originating HCC tumors - Effective response to four commonly used empirical targeted drugs showing a dose-dependent manner	- Labor intensive 3D bioprinting procedure - Use of UV-photocrosslinking with potential cell damage risk	189
	GelMA					
3D bioprinted scaffolds	Gelatin alginate	Patient-derived HCC	Platform for personalized medicine of human hepatocellular carcinoma	- HepG2 reduced growth and high degree of stromal invasion from the nodules with cirrhotic-like stiffness compared to healthy controls - Patient-derived scaffolds with high viability and proliferation rate - Good retention of the features of the originating HCC tumors - Effective response to four commonly used empirical targeted drugs showing a dose-dependent manner	Limited 3D scaffold design and geometry in terms of biomimicry and complexity	138
	Gelatin alginate					

Table 1 (Contd.)

<i>In vitro</i> model	Biomaterials	Cell source	Aim of the work	Main outcomes	Limitations	Ref.
Electrospun scaffolds	Liver decellularized ECM PLLA	THLE-3 hepatocytes	Nanofibrous hepatic-like scaffold for therapeutics research	- Bio-functional microenvironment - Cell attachment and survival - Expression of key hepatic genes - Hepatocyte growth and albumin production - Highly porous and randomly oriented nanofibrous structures - Enhanced cell attachment and spreading due to FN coating - Formation of colonies, maintenance of cell morphology and function for prolonged periods of time - High levels of CYP450 A1 enzyme activity and albumin secretion	Use of thermoplastic polymeric material with higher mechanical properties compared to the native liver tissue	195
	Chitosan FN coating	Primary rat hepatocyte and 3T3-J2 fibroblasts	Biomimetic nanofibrous scaffolds and co-culture system for the long-term maintenance of liver functions		Limited FN biomimetic potential compared to other biomaterials (e.g., decellularized ECM)	201

the ammonia detoxification cycle (e.g., Arginase I), and expression of phase I and phase II human enzymes.^{205,206} In addition, they have limited sensitivity for the prediction of human drug hepatotoxicity.²⁰⁷ In contrast, non-hepatic stem cells are usually suitable for investigating specific liver diseases and characteristic functions.^{208–210} Moreover, *in vitro* models and testing strategies aim to tackle the current challenge of properly mimicking the liver microenvironment, thus providing insights into the recreation of the *in vivo* physiology. Consequently, it is believed that a visionary road towards compliant materials for LTE relies on the manipulation and decellularization of ECM, which can appropriately preserve the hepatic microenvironment allowing for a comprehensive *in vitro* mimicry.^{124,211} Moreover, shortcomings in ECM availability may result in major drawbacks. On the other hand, in recent years this strategy has been gaining increased attention. Although 2D cultures are more convenient in terms of costs and ease of use, they do not reflect the *in vivo* conditions, due to low cell bioactivity and lacks in functional morphology.^{212–214} For this reason, 3D cultures allow for building more complex models to sustain the development of thorough toxicity studies, high-throughput drug screening platforms, and pathophysiology applications. However, *in vitro* research outcomes may be generally difficult to adapt thoroughly to *in vivo* human models. Such data adaptation is often performed by multiplying the maximum plasma concentration by a factor of 20× to 100×.^{215,216} On the other side, different pathways and mechanisms of toxicity of tested drug compounds may arise when using a wide range of concentrations.²¹⁷ Similarly, drug concentrations relevant to the human *in vivo* situation should be strictly controlled;²³ and effective dose calculation, blood volume, and cell number may diverge.^{218–220} To obtain these 3D *in vitro* LTE constructs, various approaches have been employed, and among others, there are organoids, liver-on-a-chip(s), and scaffolding techniques (e.g., electrospinning, 3D-bioprinting). In particular, liver-on-a-chip platforms can provide a dynamic microenvironment that allows for mimicking the perfusion flow system required for tissue vascularization.^{122,221} Such perfusable systems are more adequate for long-term studies to in-depth investigate liver tissue maturation under controllable fluid-dynamic stimuli (e.g., biochemical stimulation, signaling transduction) and for drug testing.^{105,222} Moreover, microfluidics allows for mimicking liver zonation and metabolism, which are still considered challenging when using 3D models such as organoids and scaffolds due to the complex liver physiology and heterogeneity.¹⁰⁷ To our knowledge, a few studies successfully achieved liver zonation by using organoids²²³ and scaffold-based technologies.¹⁸⁷ Nevertheless, such studies still rely on the use of microfluidic-based technologies.

Although recent advances focus on more automated biofabrication approaches to avoid significant errors and bias, it is still strongly believed that a further step towards this research direction should be made. As a result, the data-driven repeatability of analytical methods for drug testing and toxicity studies would actively encourage predicting and identifying



Table 2 Summary of advantages and disadvantages of *in vitro* models for human liver diseases and drug screening

<i>In vitro</i> model	Advantages	Disadvantages
Organoids	• Cost-effective procedure • Facile method • Ability to easily combine different cell types • Cells self-organization properties • Cell–cell contact and interaction to reproduce <i>in vivo</i> conditions • Ability to mimic oxygen gradients and drug diffusion of the liver lobule • Easy integration into 3D scaffold/microfluidic platform • Long-term culture and maintenance of the overall metabolic configuration and liver-specific functionality • Suitable for combination with soft biomaterials (<i>i.e.</i>, hydrogels) • Allow the development of personalized model by using patient-derived tissue biopsies or pluripotent stem cells	• Labor-intensive procedures to develop suitable fabrication protocols • Use of expensive cell sources (<i>i.e.</i>, iPSC) • Relatively simple model with lack of flexibility enabling to reproduce complex tissue architecture and hierarchical structure • Limited control on organoid size and uniformity • Lack of vascularization • Limited tissue availability in case of patient-derived tissue biopsies
Liver-on-a-chip	• Cost-effective • Ability to recreate tissue-like microarchitecture by tailoring and adapting different layouts and design • Low number of cells required and amount of tissue culture medium • Ability to recreate the <i>in vivo</i> liver natural and pathological physiology by generating dynamic mechanical and physicochemical stimuli • Ability to introduce fluidic channels to reproduce dynamic blood flow, wall shear stress, oxygen gradient, and metabolic zonation • Precise cell spatial distribution • Ability to mimic the liver tissue functional unit (<i>i.e.</i>, sinusoid, canicular system, acinus) • Ability to mimic molecular mechanism of disease and drug action • Recapitulation of tissue/organ multi-cellular architectures and tissue–tissue interfaces to evaluate interorgan and intertissue interaction in drug metabolism.	• Expensive technology for the fabrication of the microfluidic platform • Low throughput • Multi-step fabrication process • Large amount of dead space • Not specific drug bindings to the chip biomaterial platform • Expensive device (<i>i.e.</i>, bioreactor, syringe pumps) coupled to the microfluidic chip to create <i>in vivo</i> condition • Not suitable to reproduce physiological tissue-like structures in terms of complexity and size • Limited selection of biomaterials to recreate a biomimetic microenvironment
3D scaffolds	• High control over scaffold architecture and pore size • Suitable for the fabrication of highly biomimetic construct in terms of tissue architectures and biomaterials • Ability to precisely position different cell types and biomaterials to reproduce the complexity of the heterogeneous liver microenvironment in pathological and physiological state • Tissue-like cell density and composition • Ability to load biomaterials with drug compounds • Ability to fabricate constructs with different mechanical properties by easily changing fabrication parameter processes	• Complex and expensive biofabrication apparatus Labor-intensive biofabrication procedures • Challenging coupling of materials and biofabrication techniques suitable to create complex and high-resolution structure • Not suitable to reproduce <i>in vivo</i>-like stimuli without perfusable systems • Material choice not always highly ECM biomimetic • Limited range of fabrication techniques allowing for functional cell encapsulation

possible outcomes of these pioneering biomedical technologies.²²⁴ Moreover, bioinformatics would speed up the final process involving governmental agencies (*e.g.*, FDA approval, EC regulations) to authorize and market such advanced LTE *in vitro* tools at a commercial scale. Among others, deep learning methods for DILI prediction and toxicogenomic have been lately realized.^{225–230} In this frame, machine learning algorithms have been applied to the chemical structure of small molecule drugs as a model to predict the DILI compound-specific risk at the preclinical stage and to identify patient-specific drug treatments.²²⁵ Similarly, an artificial intelligence-based approach was developed to forecast and rank gene expression features acquired from rodent livers exposed to

drug compounds. A toxicogenomic open database²³¹ was used to extract such features to predict liver toxicity, while the computational model was optimized to predict whether a drug compound can cause liver necrosis and identify target gene biomarkers as disease indicators.²²⁸ Here, the model identified predictor biomarkers that are involved in liver metabolism and detoxification (*i.e.*, Car3, Crat, Cyp39a1, Dcd, Lbp, Scly, Slc23a1, and Tkfc), carcinogenesis as well as transcriptional regulation (*i.e.*, Ablim3). In the future, similar methods could be used to boost the prediction of drug toxicity effects in humans. In fact, developing machine learning algorithms and bioinformatics methodologies are relatively cost-effective and could reduce the overall time to market safe drug products.



Moreover, the public debate should focus on emerging challenges such as biobanking frontiers, which would help long-term studies on patient-derived liver tissues for drug development. These biological samples, which can be collected in-hospital or during community screenings, can be maintained and used at a later stage for research purposes, at the border with healthcare outputs. Importantly, the engineered constructs should accomplish clinical-grade quality and good manufacturing practices (GMP).⁹³ Herein, organoid models may closely recapitulate both the native and the diseased organs. Parallely, they can be used to predict drug sensitivity and identify biomarkers for treatment response in different population groups. However, there is still an urgent need to fully validate the tissue heterogeneity and physiological relevance of 3D engineered *in vitro* models and the effectiveness of drug testing applications, respectively. Indeed, this would potentially allow for their clinical translation towards individualized treatments and therapy effects.²³² Therefore, it is of foremost importance to clinically validate *in vitro* outcomes in humans.^{233–235}

Similarly, somatic genome editing platforms (*e.g.*, TALEN, ZFN, CRISPR/Cas9) could be also considered as an halfway point to design liver disease models for metabolic and acquired disorders with clinical therapy purposes, thus identifying responsible genes and mutational profile of liver diseases and hepatic cancer.^{93,211} For instance, such platforms were employed to model liver disease as HCC, inducing carcinogenesis in healthy liver 3D engineered constructs such as organoids.²³⁶

6. Conclusions

The production of small-scale 3D constructs that closely mimic the *in vivo* hepatic microenvironment is at the present a concrete option for disease modeling and drug testing. However, one of the primary challenges for *in vitro* liver models is the generation of reliable and accurate platforms to fully reflect the physiological function of the human liver. In particular, the main challenges are found in (i) validating *in vitro* scaled down LTE structures able to recapitulate *in vivo* human models, and (ii) perfusing such engineered models for a thorough characterization of the liver's functional complexity. Therefore, controlling the overall architecture of these platforms is essential for their mechanical and biological stability.^{151,237–239} Despite recent progress towards scalable 3D liver scaffolds for drug metabolism and toxicology studies, standardized testing platforms that aim to overcome animal models are still in their infancy and lack accurate approaches for the specific prediction and repeatability of data-driven results.^{240–243} However, it is strongly believed that the rapid advance of biofabrication technologies together with an improved clinical translation might extensively enhance the knowledge on disease pathogenesis and drug development for patient-specific applications.

Abbreviations

2DMC	Two-dimensional monolayer culture
3T3-J2	Mouse embryonic fibroblasts
5-FU	5-Fluorouracil
ABCB1	Atp binding cassette subfamily B member 1
AAT	Alpha-1 antitrypsin
ACTA2	Actin alpha 2
AFP	Alpha-fetoprotein
ALD	Alcoholic liver disease
AML12	Alpha mouse liver 12 hepatocytes
APAP	Acetaminophen
ASS1	Argininosuccinate synthetase 1
CF	Cystic fibrosis
CFTR	Cystic fibrosis transmembrane conductance regulator
CLD	Chronic liver disease
COL1A1	Collagen type I alpha 1 chain
CNC	Cellulose nanocrystals
CTLN1	Citrullinemia type 1
CRISPR	Clustered regularly interspaced short palindromic repeat
CYP2C9	Cytochrome P450 family 2 subfamily C member 9
CYP3A4	Cytochrome P450 3A4
CYP450	Cytochrome P450
dECM	Decellularized extracellular matrix
DILI	Drug-induced liver injury
DNA	Deoxyribonucleic acid
DOX	Doxorubicin
ECM	Extracellular matrix
EGFR	Estimated glomerular filtration rate
EpCAM ⁺	Epithelial cell adhesion molecule positive
EtOH	Ethanol
FN	Fibronectin
GelMA	Gelatin methacryloyl
GK	Glucokinase
HA	Hyaluronic acid
HAM	Hyaluronic acid-coated microcarriers
HCC	Hepatocellular carcinoma
HCT-116	Human colon carcinoma cells
HBV	Hepatitis B virus
HepG2	Human hepatoma G2 cells
HepaRG	Human hepatic progenitor cells
hESC	Human embryonic stem cells
hFLMC	Human fetal liver mesenchymal cells
HHH	Healthy human hepatocytes
hiHEP	Human induced hepatocytes
hiPSC	Human induced pluripotent stem cells
HLC	Hepatocyte-like cells
hLECM	Human liver extracellular matrix
HMEC-1	Human microvascular endothelial cells
HNF4A	Hepatocyte nuclear factor 4 alpha
HPC	Hepatic progenitor cells
hPH	Human primary hepatocytes
HSC	Hepatic stellate cells
HUH-7	Human hepatoma cell line 7



HUVEC	Human umbilical vein endothelial cells
IC ₅₀	Half-maximal inhibitory concentration
IGF-2	Insulin-like growth factor 2
IPN	Interpenetrating network
iPSC	Induced pluripotent stem cells
LTE	Liver tissue engineering
LX-2	Lieming Xu-2 human hepatic stellate cells
MDR-1	Multidrug resistance protein 1
MPS	Mucopolysaccharidosis
MRP1	Multidrug resistance associated protein 1
NaB	Sodium butyrate
NAFLD	Non-alcoholic fatty liver disease
NASH	Non-alcoholic steatohepatitis
NIH 3T3	Mouse embryonic fibroblasts
PCL	Polycaprolactone
PEG	Polyethylene glycol
PEGDA	Polyethylene glycol diacrylate
PHH	Primary human hepatocytes
PLA	Poly(lactide acid)
PLC	Primary liver cancer cells
PLGA	Poly-DL-lactide-co-glycolide
PLLA	Poly-L-lactic acid
pNIPAAm	Poly(N-isopropyl acrylamide)
PEPCK	Phosphoenolpyruvate carboxykinase
PRH	Primary rat hepatocytes
PU	Polyurethane
PVA	Polyvinyl alcohol
RGD	Arginine-glycine-aspartic acid
RLC-18	Rat liver cells
ROS	Reactive oxygen species
TALEN	Transcription activator-like effector nucleases
TGFβ-1	Transforming growth factor beta 1
THLE-3	Transformed human liver epithelial-3
THP-1	Tamm-horsfall protein 1 kupffer cells
TNFα	Tumour necrosis factor A
TTR	Transthyretin
VA	Valproic acid
ZFN	Zinc finger nucleases

Conflicts of interest

The authors declare no conflict of interest in this work.

Acknowledgements

A. P., M. V. and W. S. acknowledge the financial support of Warsaw University of Technology (Subvention Funds), the National Centre for Research and Developments within the STRATEGMED program (project no. STRATEGMED3/305813/2/NCBR/2017) and in the framework of the project BIOMOTION (PL-TW/VI/3/2019). This work was partially supported by the First TEAM grant number POIR.04.04.00-00-5ED7/18-00, within the framework of the First TEAM programme of the Foundation for Polish Science (FNP), co-financed by the

European Union under the European Regional Development Fund. C. R., F. P. and M. C. acknowledge the financial support from the Polish Ministry of Science and Higher Education through scholarships for outstanding young scientists. C. R. was partially supported by the Foundation for Polish Science (FNP). This study is also supported by the National Science Centre Poland (NCN) within PRELUDIUM 19 Project No. 2020/37/N/ST5/03272 to N. C. and SONATA 14 Project No. 2018/31/D/ST8/03647 to M. C.

Fig. 1, 2, 3A, 4A, 5 and 6, and the graphical abstract are created with Biorender.com.

References

- 1 S. Kishi, T. Matsumoto, T. Ichimura and C. R. Brooks, *In Vitro Cell. Dev. Biol.*, 2021, 1–15.
- 2 A. Rizki-Safitri, T. Traitteur and R. Morizane, *Function*, 2021, 2, zqab026.
- 3 I. Ziółkowska-Suchanek, *Cells*, 2021, 10, 141.
- 4 B. Cuniff, J. E. Druso and J. L. van der Velden, *Histochem. Cell Biol.*, 2021, 1–8.
- 5 I. Kulvinskiene, R. Aldonyte, R. Miksiunas, A. Mobasheri and D. Bironaite, *Cell Biol. Transl. Med. Vol. 10 Stem Cells Tissue Regen*, 2020, pp. 43–77.
- 6 C. Gardin, L. Ferroni, C. Latremouille, J. C. Chachques, D. Mitrećić and B. Zavan, *Cells*, 2020, 9, 742.
- 7 M. Costantini, S. Testa, E. Fornetti, C. Fuoco, C. Sanchez Riera, M. Nie, S. Bernardini, A. Rainer, J. Baldi and C. Zoccali, *EMBO Mol. Med.*, 2021, 13, e12778.
- 8 M. Costantini, S. Testa, P. Mozetic, A. Barbetta, C. Fuoco, E. Fornetti, F. Tamiro, S. Bernardini, J. Jaroszewicz, W. Swieszkowski, M. Trombetta, L. Castagnoli, D. Seliktar, P. Garstecki, G. Cesareni, S. Cannata, A. Rainer, C. Gargioli, W. Świąszkowski, M. Trombetta, L. Castagnoli, D. Seliktar, P. Garstecki, G. Cesareni, S. Cannata, A. Rainer and C. Gargioli, *Biomaterials*, 2017, 131, 98–110.
- 9 S. Cheemerla and M. Balakrishnan, *Clin. Liver Dis.*, 2021, 17, 365.
- 10 R. P. Cunningham and N. Porat-Shliom, *Front. Physiol.*, 2021, 12, 1–17.
- 11 J. Ozougwu and J. C. Ozougwu, *Int. J. Res. Pharm. Biosci.*, 2017, 4, 13.
- 12 A. S. Serras, J. S. Rodrigues, M. Cipriano, A. V. Rodrigues, N. G. Oliveira and J. P. Miranda, *Front. Cell Dev. Biol.*, 2021, 9, 1–30.
- 13 Y. Tao, M. Wang, E. Chen and H. Tang, *Mediators Inflammation*, 2017, 4256352.
- 14 G. K. Michalopoulos and B. Bhushan, *Nat. Rev. Gastroenterol. Hepatol.*, 2021, 18, 40–55.
- 15 W. Li, L. Li and L. Hui, *Trends Cell Biol.*, 2020, 30, 329–338.
- 16 H. Lee, S. Chae, J. Y. Kim, W. Han, J. Kim, Y. Choi and D. W. Cho, *Biofabrication*, 2019, 11(2), 025001.



- 17 M. Raasch, E. Fritsche, A. Kurtz, M. Bauer and A. S. Mosig, *Adv. Drug Delivery Rev.*, 2019, **140**, 51–67.
- 18 X. Ma, J. Liu, W. Zhu, M. Tang, N. Lawrence, C. Yu, M. Gou and S. Chen, *Adv. Drug Delivery Rev.*, 2018, **132**, 235–251.
- 19 Y. Parmentier, C. Pothier, N. Hewitt, L. Vincent, F. Caradec, J. Liu, F. Lin, M.-M. Trancart, F. Guillet and B. Bouaita, *Xenobiotica*, 2019, **49**, 22–35.
- 20 Y. Kim, K. Kang, S. Yoon, J. S. Kim, S. A. Park, W. D. Kim, S. B. Lee, K.-Y. Ryu, J. Jeong and D. Choi, *Organogenesis*, 2018, **14**, 1–12.
- 21 E. Milner, M. Ainsworth, M. McDonough, B. Stevens, J. Buehrer, R. Delzell, C. Wilson and J. Barnhill, *Med. Drug Discovery*, 2020, **8**, 100060.
- 22 C. M. Smith, C. K. Nolan, M. A. Edwards, J. B. Hatfield, T. W. Stewart, S. S. Ferguson, E. L. Lecluyse and J. Sahi, *J. Pharm. Sci.*, 2012, **101**, 3989–4002.
- 23 M. Vinken and J. G. Hengstler, *Arch. Toxicol.*, 2018, **92**, 2981–2986.
- 24 M. R. McGill and H. Jaeschke, *Biochim. Biophys. Acta, Mol. Basis Dis.*, 2019, **1865**, 1031–1039.
- 25 K. Yoshizato and C. Tateno, *Expert Opin. Drug Metab. Toxicol.*, 2013, **9**, 1419–1435.
- 26 Y. A. Nevzorova, Z. Boyer-Diaz, F. J. Cubero and J. Gracia-Sancho, *J. Hepatol.*, 2020, **73**, 423–440.
- 27 K. Sakabe, T. Takebe and A. Asai, *Clin. Liver Dis.*, 2020, **15**, 3–8.
- 28 C. H. Beckwitt, A. M. Clark, S. Wheeler, D. L. Taylor, D. B. Stolz, L. Griffith and A. Wells, *Exp. Cell Res.*, 2018, **363**, 15–25.
- 29 R. D. Pedde, B. Mirani, A. Navaei, T. Styan, S. Wong, M. Mehrali, A. Thakur, N. K. Mohtaram, A. Bayati, A. Dolatshahi-Pirouz, M. Nikkhah, S. M. Willerth and M. Akbari, *Adv. Mater.*, 2017, **29**, 1606061.
- 30 J. S. Miller, K. R. Stevens, M. T. Yang, B. M. Baker, D.-H. T. Nguyen, D. M. Cohen, E. Toro, A. A. Chen, P. A. Galie and X. Yu, *Nat. Mater.*, 2012, **11**, 768–774.
- 31 L. R. Madden, T. V. Nguyen, S. Garcia-Mojica, V. Shah, A. V. Le, A. Peier, R. Visconti, E. M. Parker, S. C. Presnell and D. G. Nguyen, *iScience*, 2018, **2**, 156–167.
- 32 J. Sarkar, S. C. Kamble and N. C. Kashikar, *Chem*, 2021, **3**, 164–181.
- 33 M. A. Lancaster and J. A. Knoblich, *Science*, 2014, **345**, 1247125.
- 34 M. Simian and M. J. Bissell, *J. Cell Biol.*, 2017, **216**, 31–40.
- 35 M. Hofer and M. P. Lutolf, *Nat. Rev. Mater.*, 2021, **6**, 402–420.
- 36 T. Agarwal, N. Celikkin, M. Costantini, T. K. Maiti and P. Makvandi, *Bio-Des. Manuf.*, 2021, **4**, 641–674.
- 37 V. Magno, A. Meinhardt and C. Werner, *Adv. Funct. Mater.*, 2020, **30**, 2000097.
- 38 E. A. Aisenbrey and W. L. Murphy, *Nat. Rev. Mater.*, 2020, **5**, 539–551.
- 39 M. T. Kozlowski, C. J. Crook and H. T. Ku, *Commun. Biol.*, 2021, **4**, 1–15.
- 40 Y. Wang, H. Liu, M. Zhang, H. Wang, W. Chen and J. Qin, *Biomater. Sci.*, 2020, **8**, 5476–5488.
- 41 B. J. Klotz, L. A. Oosterhoff, L. Utomo, K. S. Lim, Q. Vallmajo-Martin, H. Clevers, T. B. F. Woodfield, A. J. W. P. Rosenberg, J. Malda and M. Ehrbar, *Adv. Healthcare Mater.*, 2019, **8**, 1900979.
- 42 M. Saheli, M. Sepantafar, B. Pournasr, Z. Farzaneh, M. Vosough, A. Piryaee and H. Baharvand, *J. Cell. Biochem.*, 2018, **119**, 4320–4333.
- 43 M. Krüger, L. A. Oosterhoff, M. E. van Wolferen, S. A. Schiele, A. Walther, N. Geijsen, L. De Laporte, L. J. W. van der Laan, L. M. Kock and B. Spee, *Adv. Healthcare Mater.*, 2020, **9**, 1901658.
- 44 S. Ye, J. W. B. Boeter, M. Mihajlovic, F. G. van Steenbeek, M. E. van Wolferen, L. A. Oosterhoff, A. Marsee, M. Caiazzo, L. J. W. van der Laan and L. C. Penning, *Adv. Funct. Mater.*, 2020, **30**, 2000893.
- 45 N. Brogiere, L. Isenmann, C. Hirt, T. Ringel, S. Placzek, E. Cavalli, F. Ringnald, L. Villiger, R. Züllig and R. Lehmann, *Adv. Mater.*, 2018, **30**, 1801621.
- 46 T. Takebe, K. Sekine, M. Kimura, E. Yoshizawa, S. Ayano, M. Koido, S. Funayama, N. Nakanishi, T. Hisai, T. Kobayashi, T. Kasai, R. Kitada, A. Mori, H. Ayabe, Y. Ejiri, N. Amimoto, Y. Yamazaki, S. Ogawa, M. Ishikawa, Y. Kiyota, Y. Sato, K. Nozawa, S. Okamoto, Y. Ueno and H. Taniguchi, *Cell Rep.*, 2017, **21**, 2661–2670.
- 47 R. Ouchi, S. Togo, M. Kimura, T. Shinozawa, M. Koido, H. Koike, W. Thompson, R. A. Karns, C. N. Mayhew, P. S. McGrath, H. A. McCauley, R.-R. Zhang, K. Lewis, S. Hakozaiki, A. Ferguson, N. Saiki, Y. Yoneyama, I. Takeuchi, Y. Mabuchi, C. Akazawa, H. Y. Yoshikawa, J. M. Wells and T. Takebe, *Cell Metab.*, 2019, **30**, 374–384.
- 48 F. Sampaziotis, M. Cardoso de Brito, P. Madrigal, A. Bertero, K. Saeb-Parsy, F. A. C. Soares, E. Schruppf, E. Melum, T. H. Karlsen, J. A. Bradley, W. T. H. Gelson, S. Davies, A. Baker, A. Kaser, G. J. Alexander, N. R. F. Hannan and L. Vallier, *Nat. Biotechnol.*, 2015, **33**, 845–852.
- 49 M. Ogawa, S. Ogawa, C. E. Bear, S. Ahmadi, S. Chin, B. Li, M. Grompe, G. Keller, B. M. Kamath and A. Ghanekar, *Nat. Biotechnol.*, 2015, **33**, 853–861.
- 50 S. Wang, X. Wang, Z. Tan, Y. Su, J. Liu, M. Chang, F. Yan, J. Chen, T. Chen, C. Li, J. Hu and Y. Wang, *Cell Res.*, 2019, **29**, 1009–1026.
- 51 Y. Guan, D. Xu, P. M. Garfin, U. Ehmer, M. Hurwitz, G. Enns, S. Michie, M. Wu, M. Zheng, T. Nishimura, J. Sage and G. Peltz, *JCI Insight*, 2017, **2**, e94954.
- 52 M. Coll, L. Perea, R. Boon, S. B. Leite, J. Vallverdú, I. Mannaerts, A. Smout, A. El Taghdouini, D. Blaya, D. Rodrigo-Torres, I. Graupera, B. Aguilar-Bravo, C. Chesne, M. Najimi, E. Sokal, J. J. Lozano, L. A. van Grunsven, C. M. Verfaillie and P. Sancho-Bru, *Cell Stem Cell*, 2018, **23**, 101–113.
- 53 S. S. Ng, K. Saeb-Parsy, S. J. I. Blackford, J. M. Segal, M. P. Serra, M. Horcas-Lopez, S. Mastoridis, W. Jassem, C. W. Frank and N. J. Cho, *Biomaterials*, 2018, **182**, 299–311.



- 54 M. N. B. Ramli, Y. S. Lim, C. T. Koe, D. Demircioglu, W. Tng, K. A. U. Gonzales, C. P. Tan, I. Szczerbinska, H. Liang and E. L. Soe, *Gastroenterology*, 2020, **159**, 1471–1486.
- 55 C. J. Hindley, L. Cordero-Espinoza and M. Huch, *Dev. Biol.*, 2016, **420**, 251–261.
- 56 S. J. Mun, Y.-H. Hong, H.-S. Ahn, J.-S. Ryu, K.-S. Chung and M. J. Son, *Int. J. Stem Cells*, 2020, **13**, 279–286.
- 57 J. Vives and L. Batlle-Morera, *Stem Cell Res. Ther.*, 2020, **11**, 1–4.
- 58 J.-Y. Lee, H.-J. Han, S.-J. Lee, E.-H. Cho, H.-B. Lee, J.-H. Seok, H. S. Lim and W.-C. Son, *Int. J. Mol. Sci.*, 2020, **21**, 2982.
- 59 N. Dianat, H. Dubois-Pot-Schneider, C. Steichen, C. Desterke, P. Leclerc, A. Raveux, L. Combettes, A. Weber, A. Corlu and A. Dubart-Kupperschmitt, *Hepatology*, 2014, **60**, 700–714.
- 60 S. B. Leite, T. Roosens, A. El Taghdouini, I. Mannaerts, A. J. Smout, M. Najimi, E. Sokal, F. Noor, C. Chesne and L. A. van Grunsven, *Biomaterials*, 2016, **78**, 1–10.
- 61 B. Artegiani, L. van Voorthuijsen, R. G. H. Lindeboom, D. Seinstra, I. Heo, P. Tapia, C. López-Iglesias, D. Postrach, T. Dayton and R. Oka, *Cell Stem Cell*, 2019, **24**, 927–943.
- 62 A. Correns, L.-M. A. Zimmermann, C. Baldock and G. Sengle, *Matrix Biol. Plus*, 2021, **11**, 100071.
- 63 M. Urbischek, H. Rannikmae, T. Foets, K. Ravn, M. Hyvönen and M. de la Roche, *Sci. Rep.*, 2019, **9**, 1–11.
- 64 T. Tao, P. Deng, Y. Wang, X. Zhang, Y. Guo, W. Chen and J. Qin, *Adv. Sci.*, 2022, **9**, 2103495.
- 65 Y. Lu, G. Zhang, C. Shen, K. Uygun, M. L. Yarmush and Q. Meng, *Biotechnol. Bioeng.*, 2012, **109**, 595–604.
- 66 C. M. Gamboa, Y. Wang, H. Xu, K. Kalemba, F. E. Wondisford and H. E. Sabaawy, *Cells*, 2021, **10**, 3280.
- 67 G. Hong, J. Kim, H. Oh, S. Yun, C. M. Kim, Y. Jeong, W. Yun, J. Shim, I. Jang and C. Kim, *Adv. Mater.*, 2021, 2102624.
- 68 T. Takebe and J. M. Wells, *Science*, 2019, **364**, 956–959.
- 69 P. N. Bernal, M. Bouwmeester, J. Madrid-Wolff, M. Falandt, S. Florczak, N. G. Rodriguez, Y. Li, G. Größbacher, R. Samsom and M. van Wolferen, *Adv. Mater.*, 2022, 2110054.
- 70 M. A. Lancaster, M. Renner, C.-A. Martin, D. Wenzel, L. S. Bicknell, M. E. Hurles, T. Homfray, J. M. Penninger, A. P. Jackson and J. A. Knoblich, *Nature*, 2013, **501**, 373–379.
- 71 T. Takebe, K. Sekine, M. Enomura, H. Koike, M. Kimura, T. Ogaeri, R.-R. Zhang, Y. Ueno, Y.-W. Zheng, N. Koike, S. Aoyama, Y. Adachi and H. Taniguchi, *Nature*, 2013, **499**, 481–484.
- 72 S. Akbari, G. G. Sevinç, N. Ersoy, O. Basak, K. Kaplan, K. Sevinç, E. Ozel, B. Sengun, E. Enustun, B. Ozcimen, A. Bagriyanik, N. Arslan, T. T. Önder and E. Erdal, *Stem Cell Rep.*, 2019, **13**, 627–641.
- 73 Y.-Z. Nie, Y.-W. Zheng, K. Miyakawa, S. Murata, R.-R. Zhang, K. Sekine, Y. Ueno, T. Takebe, T. Wakita and A. Ryo, *EBioMedicine*, 2018, **35**, 114–123.
- 74 Y. Xia, A. Carpentier, X. Cheng, P. D. Block, Y. Zhao, Z. Zhang, U. Protzer and T. J. Liang, *J. Hepatol.*, 2017, **66**, 494–503.
- 75 S. Nuciforo, I. Fofana, M. S. Matter, T. Blumer, D. Calabrese, T. Boldanova, S. Piscuoglio, S. Wieland, F. Ringnalda and G. Schwank, *Cell Rep.*, 2018, **24**, 1363–1376.
- 76 G. Gómez-Mariano, N. Matamala, S. Martínez, I. Justo, A. Marcacuzco, C. Jimenez, S. Monzón, I. Cuesta, C. Garfia and M. T. Martínez, *Hepatol. Int.*, 2020, **14**, 127–137.
- 77 L. Broutier, G. Mastrogianni, M. M. A. Verstegen, H. E. Francies, L. M. Gavarró, C. R. Bradshaw, G. E. Allen, R. Arnes-Benito, O. Sidorova and M. P. Gaspersz, *Nat. Med.*, 2017, **23**, 1424–1435.
- 78 G. H. Underhill and S. R. Khetani, *Cell. Mol. Gastroenterol. Hepatol.*, 2018, **5**, 426–439.
- 79 W. C. Peng, L. J. Kraaier and T. A. Kluiver, *Exp. Mol. Med.*, 2021, 1–17.
- 80 Y. Jin, J. Kim, J. S. Lee, S. Min, S. Kim, D.-H. Ahn, Y.-G. Kim and S.-W. Cho, *Adv. Funct. Mater.*, 2018, **28**, 1801954.
- 81 T. Shinozawa, M. Kimura, Y. Cai, N. Saiki, Y. Yoneyama, R. Ouchi, H. Koike, M. Maezawa, R.-R. Zhang and A. Dunn, *Gastroenterology*, 2021, **160**, 831–846.
- 82 A. Skardal, M. Devarasetty, C. Rodman, A. Atala and S. Soker, *Ann. Biomed. Eng.*, 2015, **43**, 2361–2373.
- 83 N. Kaplowitz, *Nat. Rev. Drug Discovery*, 2005, **4**, 489–499.
- 84 N. Prior, P. Inacio and M. Huch, *Gut*, 2019, **68**, 2228–2237.
- 85 L. Meunier and D. Larrey, *Front. Pharmacol.*, 2019, **10**, 1482.
- 86 S. J. Mun, J.-S. Ryu, M.-O. Lee, Y. S. Son, S. J. Oh, H.-S. Cho, M.-Y. Son, D.-S. Kim, S. J. Kim, H. J. Yoo, H.-J. Lee, J. Kim, C.-R. Jung, K.-S. Chung and M. J. Son, *J. Hepatol.*, 2019, **71**, 970–985.
- 87 M. Sgodda, Z. Dai, R. Zweigerdt, A. D. Sharma, M. Ott and T. Cantz, *Stem Cells Dev.*, 2017, **26**, 1490–1504.
- 88 S. H. Au, M. D. Chamberlain, S. Mahesh, M. V. Sefton and A. R. Wheeler, *Lab Chip*, 2014, **14**, 3290–3299.
- 89 M. C. Bouwmeester, P. N. Bernal, L. A. Oosterhoff, M. van Wolferen, V. Lehmann, M. Vermaas, M. Buchholz, Q. Peiffer, J. Malda and L. J. W. van der Laan, *Macromol. Biosci.*, 2021, 2100327.
- 90 T. Nakamura, K. Yoshimoto, Y. Nakayama, Y. Tomita and A. Ichihara, *Proc. Natl. Acad. Sci. U. S. A.*, 1983, **80**, 7229–7233.
- 91 T. Matsui and T. Shinozawa, *Front. Genet.*, 2021, 2119.
- 92 S. Nuciforo and M. H. Heim, *JHEP Rep.*, 2021, **3**, 100198.
- 93 S. N. Boers, J. J. M. van Delden, H. Clevers and A. L. Bredenoord, *EMBO Rep.*, 2016, **17**, 938–941.
- 94 S. N. Boers and A. L. Bredenoord, *Nat. Cell Biol.*, 2018, **20**, 642–645.
- 95 N. Sachs, J. de Ligt, O. Kopper, E. Gogola, G. Bounova, F. Weeber, A. V. Balgobind, K. Wind, A. Gracanin and H. Begthel, *Cell*, 2018, **172**, 373–386.
- 96 L. R. Volpatti and A. K. Yetisen, *Trends Biotechnol.*, 2014, **32**, 347–350.



- 97 X. Hou, Y. S. Zhang, G. T. Santiago, M. M. Alvarez, J. Ribas, S. J. Jonas, P. S. Weiss, A. M. Andrews, J. Aizenberg and A. Khademhosseini, *Nat. Rev. Mater.*, 2017, **2**, 1–15.
- 98 S. Faley, K. Seale, J. Hughey, D. K. Schaffer, S. VanCompernelle, B. McKinney, F. Baudenbacher, D. Unutmaz and J. P. Wikswo, *Lab Chip*, 2008, **8**, 1700–1712.
- 99 D. Patel, A. Haque, Y. Gao and A. Revzin, *Integr. Biol.*, 2015, **7**, 815–824.
- 100 C.-T. Ho, R.-Z. Lin, R.-J. Chen, C.-K. Chin, S.-E. Gong, H.-Y. Chang, H.-L. Peng, L. Hsu, T.-R. Yew and S.-F. Chang, *Lab Chip*, 2013, **13**, 3578–3587.
- 101 P. Gissen and I. M. Arias, *J. Hepatol.*, 2015, **63**, 1023–1037.
- 102 F. Yu, R. Deng, W. Hao Tong, L. Huan, N. Chan Way, A. IslamBadhan, C. Iliescu and H. Yu, *Sci. Rep.*, 2017, **7**, 14528.
- 103 D. Huang, S. B. Gibeley, C. Xu, Y. Xiao, O. Celik, H. N. Ginsberg and K. W. Leong, *Adv. Funct. Mater.*, 2020, **30**, 1909553.
- 104 C. E. Suurmond, S. Lasli, F. W. van den Dolder, A. Ung, H. Kim, P. Bandaru, K. Lee, H. Cho, S. Ahadian and N. Ashammakhi, *Adv. Healthcare Mater.*, 2019, **8**, 1901379.
- 105 B. Vinci, D. Cavallone, G. Vozzi, D. Mazzei, C. Domenici, M. Brunetto and A. Ahluwalia, *Biotechnol. J.*, 2010, **5**, 232–241.
- 106 W. J. McCarty, O. B. Usta and M. L. Yarmush, *Sci. Rep.*, 2016, **6**, 1–10.
- 107 R. Panday, C. P. Monckton and S. R. Khetani, in *Seminars in Liver Disease*, Thieme Medical Publishers, Inc., 2022, vol. 42, pp. 1–16.
- 108 J. Ahn, J.-H. Ahn, S. Yoon, Y. S. Nam, M.-Y. Son and J.-H. Oh, *J. Biol. Eng.*, 2019, **13**, 1–15.
- 109 J.-H. Lee, K.-L. Ho and S.-K. Fan, *J. Biomed. Sci.*, 2019, **26**, 88.
- 110 P. J. Lee, P. J. Hung and L. P. Lee, *Biotechnol. Bioeng.*, 2007, **97**, 1340–1346.
- 111 J. B. Lee, J. S. Park, Y. M. Shin, D. H. Lee, J. Yoon, D. Kim, U. H. Ko, Y. Kim, S. H. Bae and H. Sung, *Adv. Funct. Mater.*, 2019, **29**, 1900075.
- 112 B. Bulutoglu, C. Rey-Bedón, Y. B. A. Kang, S. Mert, M. L. Yarmush and O. B. Usta, *Lab Chip*, 2019, **19**, 3022–3031.
- 113 A. Sato, K. Kadokura, H. Uchida and K. Tsukada, *Biochem. Biophys. Res. Commun.*, 2014, **453**, 767–771.
- 114 A. Moya, M. Ortega-Ribera, X. Guimerà, E. Sowade, M. Zea, X. Illa, E. Ramon, R. Villa, J. Gracia-Sancho and G. Gabriel, *Lab Chip*, 2018, **18**, 2023–2035.
- 115 F. T. Lee-Montiel, S. M. George, A. H. Gough, A. D. Sharma, J. Wu, R. DeBiasio, L. A. Verneti and D. L. Taylor, *Exp. Biol. Med.*, 2017, **242**, 1617–1632.
- 116 L. A. Verneti, N. Senutovitch, R. Boltz, R. DeBiasio, T. Ying Shun, A. Gough and D. L. Taylor, *Exp. Biol. Med.*, 2015, **241**, 101–114.
- 117 A. Skardal, M. Devarasetty, S. Soker and A. R. Hall, *Biofabrication*, 2015, **7**, 31001.
- 118 Y. Miyamoto, M. Ikeuchi, H. Noguchi, T. Yagi and S. Hayashi, *Cell Med.*, 2015, **8**, 47–56.
- 119 M. Jang, P. Neuzil, T. Volk, A. Manz and A. Kleber, *Biomicrofluidics*, 2015, **9**, 34113.
- 120 K. M. Birksak, R. DeBiasio, M. Miedel, A. Alsebah, R. Reddinger, A. Saleh, T. Shun, L. A. Verneti and A. Gough, *Toxicology*, 2021, **450**, 152667.
- 121 M. S. Freag, B. Namgung, M. E. Reyna Fernandez, E. Gherardi, S. Sengupta and H. L. Jang, *Hepatol. Commun.*, 2021, **5**, 217–233.
- 122 K.-J. Jang, M. A. Otieno, J. Ronxhi, H.-K. Lim, L. Ewart, K. R. Kodella, D. B. Petropolis, G. Kulkarni, J. E. Rubins, D. Conegliano, J. Nawroth, D. Simic, W. Lam, M. Singer, E. Barale, B. Singh, M. Sonee, A. J. Streeter, C. Manthey, B. Jones, A. Srivastava, L. C. Andersson, D. Williams, H. Park, R. Barrile, J. Sliz, A. Herland, S. Haney, K. Karalis, D. E. Ingber and G. A. Hamilton, *Sci. Transl. Med.*, 2019, **11**, eaax5516.
- 123 J. C. Nawroth, D. B. Petropolis, D. V. Manatakis, T. I. Maulana, G. Burchett, K. Schlünder, A. Witt, A. Shukla, K. Kodella and J. Ronxhi, *Cell Rep.*, 2021, **36**, 109393.
- 124 H. Lee, W. Han, H. Kim, D.-H. Ha, J. Jang, B. S. Kim and D.-W. Cho, *Biomacromolecules*, 2017, **18**, 1229–1237.
- 125 S. Lu, F. Cuzzucoli, J. Jiang, L.-G. Liang, Y. Wang, M. Kong, X. Zhao, W. Cui, J. Li and S. Wang, *Lab Chip*, 2018, **18**, 3379–3392.
- 126 Y.-C. Toh, T. C. Lim, D. Tai, G. Xiao, D. van Noort and H. Yu, *Lab Chip*, 2009, **9**, 2026–2035.
- 127 A. Carraro, W.-M. Hsu, K. M. Kulig, W. S. Cheung, M. L. Miller, E. J. Weinberg, E. F. Swart, M. Kaazempur-Mofrad, J. T. Borenstein, J. P. Vacanti and C. Neville, *Biomed. Microdevices*, 2008, **10**, 795–805.
- 128 T. Agarwal, B. Subramanian and T. K. Maiti, *ACS Biomater. Sci. Eng.*, 2019, **5**, 4167–4182.
- 129 S. Mohanty, L. B. Larsen, J. Trifol, P. Szabo, H. V. R. Burri, C. Canali, M. Dufva, J. Emnéus and A. Wolff, *Mater. Sci. Eng., C*, 2015, **55**, 569–578.
- 130 Y. Liu, L. Zhang, J. Wei, S. Yan, J. Yu and X. Li, *J. Mater. Chem. B*, 2014, **2**, 3029–3040.
- 131 Y. Pang, Y. Horimoto, S. Sutoko, K. Montagne, M. Shinohara, D. Mathiue, K. Komori, M. Anzai, T. Niino and Y. Sakai, *Biofabrication*, 2016, **8**, 35016.
- 132 W. Xu, X. Wang, Y. Yan and R. Zhang, *J. Bioact. Compat. Polym.*, 2008, **23**, 409–422.
- 133 E. S. Place, J. H. George, C. K. Williams and M. M. Stevens, *Chem. Soc. Rev.*, 2009, **38**, 1139–1151.
- 134 K. R. Stevens, J. S. Miller, B. L. Blakely, C. S. Chen and S. N. Bhatia, *J. Biomed. Mater. Res., Part A*, 2015, **103**, 3331–3338.
- 135 R. Grant, D. Hay and A. Callanan, *Biomed. Phys. Eng. Express*, 2018, **4**, 65015.
- 136 N. Contessi Negrini, A. Angelova Volponi, P. T. Sharpe and A. D. Celiz, *ACS Biomater. Sci. Eng.*, 2021, **7**, 4330–4346.
- 137 J. P. Miranda, A. Rodrigues, R. M. Tostões, S. Leite, H. Zimmerman, M. J. T. Carrondo and P. M. Alves, *Tissue Eng., Part C*, 2010, **16**, 1223–1232.



- 138 L. Sun, H. Yang, Y. Wang, X. Zhang, B. Jin, F. Xie, Y. Jin, Y. Pang, H. Zhao, X. Lu, X. Sang, H. Zhang, F. Lin, W. Sun, P. Huang and Y. Mao, *Front. Oncol.*, 2020, **10**, 878.
- 139 X. Wang, Y. Yan, Y. Pan, Z. Xiong, H. Liu, J. Cheng, F. Liu, F. Lin, R. Wu, R. Xhang, Q. Lu, R. Zhang and Q. Lu, *Tissue Eng.*, 2006, **12**, 83–91.
- 140 J. Cui, H. Wang, Q. Shi, T. Sun, Q. Huang and T. Fukuda, *Molecules*, 2019, **24**, 1762.
- 141 B. H. Lee, H. Shirahama, M. H. Kim, J. H. Lee, N.-J. Cho and L. P. Tan, *NPG Asia Mater.*, 2017, **9**, e412.
- 142 S. Li, Z. Xiong, X. Wang, Y. Yan, H. Liu and R. Zhang, *J. Bioact. Compat. Polym.*, 2009, **24**, 249–265.
- 143 Y. Yan, X. Wang, Z. Xiong, H. Liu, F. Liu, F. Lin, R. Wu, R. Zhang and Q. Lu, *J. Bioact. Compat. Polym.*, 2005, **20**, 259–269.
- 144 S. Ye, J. W. B. Boeter, L. C. Penning, B. Spee and K. Schneeberger, *Bioengineering*, 2019, **6**.
- 145 N. S. Bhise, V. Manoharan, S. Massa, A. Tamayol, M. Ghaderi, M. Miscuglio, Q. Lang, Y. Shrike Zhang, S. R. R. yo. Shin, G. Calzone, N. Annabi, T. D. Shupe, C. E. Bishop, A. Atala, M. R. Dokmeci and A. Khademhosseini, *Biofabrication*, 2016, **8**, 014101.
- 146 J. Cui, H. Wang, Q. Shi, P. Ferraro, T. Sun, P. Dario, Q. Huang and T. Fukuda, *Acta Biomater.*, 2020, **113**, 328–338.
- 147 R. D. Hickey and W. E. Naugler, *Hepatology*, 2018, **67**, 2465–2467.
- 148 X. Wang and C. Liu, *Polymer*, 2018, **10**, 1048.
- 149 H. Bruns, U. Kneser, S. Holzhüter, B. Roth, J. Kluth, P. M. Kaufmann, D. Kluth and H. C. Fiegel, *Tissue Eng.*, 2005, **11**, 1718–1726.
- 150 Y. Li and E. Kumacheva, *Sci. Adv.*, 2018, **4**, eaas8998.
- 151 F. J. O'Brien, *Mater. Today*, 2011, **14**, 88–95.
- 152 N. A. Peppas, J. Z. Hilt, A. Khademhosseini and R. Langer, *Adv. Mater.*, 2006, **18**, 1345–1360.
- 153 D. Mondal, M. Griffith and S. S. Venkatraman, *Int. J. Polym. Mater. Polym. Biomater.*, 2016, **65**, 255–265.
- 154 Y. Zhang, Q.-S. Wang, K. Yan, Y. Qi, G.-F. Wang and Y.-L. Cui, *J. Biomed. Mater. Res., Part A*, 2016, **104**, 1863–1870.
- 155 Y. Wang, W. Su, L. Wang, L. Jiang, Y. Liu, L. Hui and J. Qin, *Toxicol. Res.*, 2018, **7**, 13–21.
- 156 S. V. Murphy and A. Atala, *Nat. Biotechnol.*, 2014, **32**, 773–785.
- 157 J. Malda, J. Visser, F. P. Melchels, T. Jüngst, W. E. Hennink, W. J. A. Dhert, J. Groll and D. W. Huttmacher, *Adv. Mater.*, 2013, **25**, 5011–5028.
- 158 A. Schwab, R. Levato, M. D'Este, S. Piluso, D. Eglin and J. Malda, *Chem. Rev.*, 2020, **120**, 11028–11055.
- 159 P. L. Lewis and R. N. Shah, *Curr. Transplant. Rep.*, 2016, **3**, 100–108.
- 160 J. W. Lee, Y.-J. Choi, W.-J. Yong, F. Pati, J.-H. Shim, K. S. Kang, I.-H. Kang, J. Park and D.-W. Cho, *Biofabrication*, 2016, **8**, 15007.
- 161 P. L. Lewis, R. M. Green and R. N. Shah, *Acta Biomater.*, 2018, **69**, 63–70.
- 162 G. Mattei, C. Magliaro, A. Pirone and A. Ahluwalia, *Organogenesis*, 2018, **14**, 129–146.
- 163 B. Wang, Q. Hu, T. Wan, F. Yang, L. Cui, S. Hu, B. Gong, M. Li and Q. C. Zheng, *Int. J. Polym. Sci.*, 2016, 2862738.
- 164 J. M. Sobral, S. G. Caridade, R. A. Sousa, J. F. Mano and R. L. Reis, *Acta Biomater.*, 2011, **7**, 1009–1018.
- 165 F. Darus, R. M. Isa, N. Mamat and M. Jaafar, *Ceram. Int.*, 2018, **44**, 18400–18407.
- 166 T. Lu, Y. Li and T. Chen, *Int. J. Nanomed.*, 2013, **8**, 337.
- 167 M. Gou, X. Qu, W. Zhu, M. Xiang, J. Yang, K. Zhang, Y. Wei and S. Chen, *Nat. Commun.*, 2014, **5**, 1–9.
- 168 J. Idaszek, M. Volpi, A. Paradiso, M. N. Quoc, Ż. Górecka, M. Klak, G. Tymicki, A. Berman, M. Wierzbicki and S. Jaworski, *Bioprinting*, 2021, **24**, e00163.
- 169 M. Volpi, A. Paradiso, M. Costantini and W. Świążkowski, *ACS Biomater. Sci. Eng.*, 2022, **8**, 379–405.
- 170 W. Peng, D. Unutmaz and I. T. Ozbolat, *Trends Biotechnol.*, 2016, **34**, 722–732.
- 171 L. A. van Grunsven, *Adv. Drug Delivery Rev.*, 2017, **121**, 133–146.
- 172 A. Faulkner-Jones, C. Fyfe, D.-J. Cornelissen, J. Gardner, J. King, A. Courtney and W. Shu, *Biofabrication*, 2015, **7**, 44102.
- 173 C. Zhong, H.-Y. Xie, L. Zhou, X. Xu and S.-S. Zheng, *Hepatobiliary Pancreatic Dis. Int.*, 2016, **15**, 512–518.
- 174 T. Hiller, J. Berg, L. Elomaa, V. Röhrs, I. Ullah, K. Schaar, A.-C. Dietrich, M. A. Al-Zeer, A. Kurtz, A. C. Hocke, S. Hippenstiel, H. Fechner, M. Weinhardt and J. Kurreck, *Int. J. Mol. Sci.*, 2018, **19**, 3129.
- 175 N. C. Negrini, N. Celikkin, P. Tarsini, S. Farè and W. Świążkowski, *Biofabrication*, 2020, **12**, 025001.
- 176 Q. Mao, Y. Wang, Y. Li, S. Juengpanich, W. Li, M. Chen, J. Yin, J. Fu and X. Cai, *Mater. Sci. Eng., C*, 2020, **109**, 110625.
- 177 M. Gori, S. M. Giannitelli, M. Torre, P. Mozetic, F. Abbruzzese, M. Trombetta, E. Traversa, L. Moroni and A. Rainer, *Adv. Healthcare Mater.*, 2020, 2001163.
- 178 V. M. Lauschke, R. Z. Shafagh, D. F. G. Hendriks and M. Ingelman-Sundberg, *Biotechnol. J.*, 2019, **14**, 1800347.
- 179 D. G. Nguyen, J. Funk, J. B. Robbins, C. Crogan-Grundy, S. C. Presnell, T. Singer and A. B. Roth, *PLoS One*, 2016, **11**, e0158674.
- 180 E. Goulart, L. C. de Caires-Junior, K. A. Telles-Silva, B. H. S. Araujo, S. A. Rocco, M. Sforca, I. L. de Sousa, G. S. Kobayashi, C. M. Musso, A. F. Assoni, D. Oliveira, E. Caldini, S. Raia, P. I. Lelkes and M. Zatz, *Biofabrication*, 2019, **12**, 15010.
- 181 H. Kizawa, E. Nagao, M. Shimamura, G. Zhang and H. Torii, *Biochem. Biophys. Rep.*, 2017, **10**, 186–191.
- 182 L. M. Norona, D. G. Nguyen, D. A. Gerber, S. C. Presnell, M. Mosedale and P. B. Watkins, *PLoS One*, 2019, **14**, e0208958.
- 183 J. Nie, Q. Gao, J. Fu and Y. He, *Adv. Healthcare Mater.*, 2020, **9**, 1901773.
- 184 M. A. Heinrich, W. Liu, A. Jimenez, J. Yang, A. Akpek, X. Liu, Q. Pi, X. Mu, N. Hu, R. M. Schifferers, J. Prakash, J. Xie and Y. S. Zhang, *Small*, 2019, **15**, 1805510.



- 185 Y. Wu, Z. Y. Lin, A. C. Wenger, K. C. Tam and X. Tang, *Bioprinting*, 2018, **9**, 1–6.
- 186 Y. Wu, A. Wenger, H. Golzar and X. Tang, *Sci. Rep.*, 2020, **10**, 20648.
- 187 G. Janani, S. Priya, S. Dey and B. B. Mandal, *ACS Appl. Mater. Interfaces*, 2022, **14**, 10167–10186.
- 188 M. Cuvelier, F. Ezan, H. Oliveira, S. Rose, J.-C. Fricain, S. Langouët, V. Legagneux and G. Baffet, *Biomaterials*, 2021, **269**, 120611.
- 189 X. Ma, C. Yu, P. Wang, W. Xu, X. Wan, C. S. E. Lai, J. Liu, A. Koroleva-Maharajh and S. Chen, *Biomaterials*, 2018, **185**, 310–321.
- 190 X. Ma, X. Qu, W. Zhu, Y.-S. Li, S. Yuan, H. Zhang, J. Liu, P. Wang, C. S. E. Lai, F. Zanella, G.-S. Feng, F. Sheikh, S. Chien and S. Chen, *Proc. Natl. Acad. Sci. U. S. A.*, 2016, **113**, 2206–2211.
- 191 F. Xie, L. Sun, Y. Pang, G. Xu, B. Jin, H. Xu, X. Lu, Y. Xu, S. Du, Y. Wang, S. Feng, X. Sang, S. Zhong, X. Wang, W. Sun, H. Zhao, H. Zhang, H. Yang, P. Huang and Y. Mao, *Biomaterials*, 2021, **265**, 120416.
- 192 M. Rahmati, D. K. Mills, A. M. Urbanska, M. R. Saeb, J. R. Venugopal, S. Ramakrishna and M. Mozafari, *Prog. Mater. Sci.*, 2021, **117**, 100721.
- 193 C. Rinoldi, E. Kijeńska, A. Chlanda, E. Chojńska, N. Khenoussi, A. Tamayol, A. Khademhosseini and W. Swieszkowski, *J. Mater. Chem. B*, 2018, **6**, 3116–3127.
- 194 I. Fasolino, V. Guarino, M. Marrese, V. Cirillo, M. Vallifuoco, M. L. Tamma, V. Vassallo, A. Bracco, F. Calise and L. Ambrosio, *Biomed. Mater.*, 2017, **13**, 15017.
- 195 R. Grant, J. Hallett, S. Forbes, D. Hay and A. Callanan, *Sci. Rep.*, 2019, **9**, 6293.
- 196 M. Mittal, M. R. Siddiqui, K. Tran, S. P. Reddy and A. B. Malik, *Antioxid. Redox Signal.*, 2014, **20**, 1126–1167.
- 197 R. Grant, D. C. Hay and A. Callanan, *Tissue Eng., Part A*, 2017, **23**, 650–662.
- 198 Y. Yokoyama, S. Hattori, C. Yoshikawa, Y. Yasuda, H. Koyama, T. Takato and H. Kobayashi, *Mater. Lett.*, 2009, **63**, 754–756.
- 199 S. Khorshidi, A. Solouk, H. Mirzadeh, S. Mazinani, J. M. Lagaron, S. Sharifi and S. Ramakrishna, *J. Tissue Eng. Regen. Med.*, 2016, **10**, 715–738.
- 200 J. H. Brown, P. Das, M. D. DiVito, D. Ivancic, L. P. Tan and J. A. Wertheim, *Acta Biomater.*, 2018, **73**, 217–227.
- 201 D. Rajendran, A. Hussain, D. Yip, A. Parekh, A. Shrirao and C. H. Cho, *J. Biomed. Mater. Res., Part A*, 2017, **105**, 2119–2128.
- 202 M. M. Sk, P. Das, A. Panwar and L. P. Tan, *Mater. Sci. Eng., C*, 2021, **123**, 111694.
- 203 F. Ghahremanzadeh, F. Alihosseini and D. Semnani, *Int. J. Biol. Macromol.*, 2021, **174**, 278–288.
- 204 Y.-H. Chen, Y.-H. Ku, K.-C. Wang, H.-C. Chiang, Y.-P. Hsu, M.-T. Cheng, C.-S. Wang and Y. Wee, *Gels*, 2022, **8**, 149.
- 205 K. Zeilinger, N. Freyer, G. Damm, D. Seehofer and F. Knöspel, *Exp. Biol. Med.*, 2016, **241**, 1684–1698.
- 206 J. V. Castell, R. Jover, C. P. Martinez-Jimenez and M. J. Gmez-Lechn, *Expert Opin. Drug Metab. Toxicol.*, 2006, **2**, 183–212.
- 207 H. H. J. Gerets, K. Tilmant, B. Gerin, H. Chanteux, B. O. Depelchin, S. Dhalluin and F. A. Atienzar, *Cell Biol. Toxicol.*, 2012, **28**, 69–87.
- 208 X. Yang, Y. Meng, Z. Han, F. Ye, L. Wei and C. Zong, *Cell Biosci.*, 2020, **10**, 1–18.
- 209 J. Deng, W. Wei, Z. Chen, B. Lin, W. Zhao, Y. Luo and X. Zhang, *Micromachines*, 2019, **10**, 676.
- 210 C. Luo, D. Lü, L. Zheng, F. Zhang, X. Zhang, S. Lü, C. Zhang, X. Jia, X. Shu and P. Li, *Biomater. Sci.*, 2021, **9**, 3776–3790.
- 211 F. Jacob, R. D. Salinas, D. Y. Zhang, P. T. T. Nguyen, J. G. Schnoll, S. Z. H. Wong, R. Thokala, S. Sheikh, D. Saxena and S. Prokop, *Cell*, 2020, **180**, 188–204.
- 212 A. J. Engler, S. Sen, H. L. Sweeney and D. E. Discher, *Cell*, 2006, **126**, 677–689.
- 213 A. Treyer and A. Müsch, *Compr. Physiol.*, 2013, **3**, 243.
- 214 C. Jensen and Y. Teng, *Front. Mol. Biosci.*, 2020, **7**, 33.
- 215 A. S. Serras, J. S. Rodrigues, M. Cipriano, A. V. Rodrigues, N. G. Oliveira and J. P. Miranda, *Front. Cell Dev. Biol.*, 2021, **9**, 626805.
- 216 W. R. Proctor, A. J. Foster, J. Vogt, C. Summers, B. Middleton, M. A. Pilling, D. Shienson, M. Kijanska, S. Ströbel, J. M. Kelm, P. Morgan, S. Messner and D. Williams, *Arch. Toxicol.*, 2017, **91**, 2849–2863.
- 217 W. Albrecht, F. Kappenberg, T. Brecklinghaus, R. Stoeber, R. Marchan, M. Zhang, K. Ebbert, H. Kirschner, M. Grinberg, M. Leist, W. Moritz, C. Cadenas, A. Ghallab, J. Reinders, N. Vartak, C. van Thriel, K. Golka, L. Tolosa, J. V. Castell, G. Damm, D. Seehofer, A. Lampen, A. Braeuning, T. Buhrke, A.-C. Behr, A. Oberemm, X. Gu, N. Kittana, B. van de Water, R. Kreiling, S. Fayyaz, L. van Aerts, B. Smedsrød, H. Ellinger-Ziegelbauer, T. Steger-Hartmann, U. Gundert-Remy, A. Zeigerer, A. Ullrich, D. Runge, S. M. L. Lee, T. S. Schiergens, L. Kuepfer, A. Aguayo-Orozco, A. Sachinidis, K. Edlund, I. Gardner, J. Rahnenführer and J. G. Hengstler, *Arch. Toxicol.*, 2019, **93**, 1609–1637.
- 218 C. Moraes, Equal contributions, J. M. Labuz, B. M. Leung, M. Inoue, T.-H. Chun and S. Takayama, *Integr. Biol.*, 2013, **5**, 1149–1161.
- 219 P. Soltantabar, E. L. Calubaquib, E. Mostafavi, A. Ghazavi and M. C. Stefan, *Organs-on-a-Chip*, 2021, **3**, 100008.
- 220 D. A. Tatosian and M. L. Shuler, *Biotechnol. Bioeng.*, 2009, **103**, 187–198.
- 221 K. Rennert, S. Steinborn, M. Gröger, B. Ungerböck, A.-M. Jank, J. Ehgartner, S. Nietzsche, J. Dinger, M. Kiehntopf and H. Funke, *Biomaterials*, 2015, **71**, 119–131.
- 222 M. Darnell, M. Ulvestad, E. Ellis, L. Weidolf and T. B. Andersson, *J. Pharmacol. Exp. Ther.*, 2012, **343**, 134–144.
- 223 M. Yamada, R. Utoh, K. Ohashi, K. Tatsumi, M. Yamato, T. Okano and M. Seki, *Biomaterials*, 2012, **33**, 8304–8315.
- 224 M. Puri, *Assay Drug Dev. Technol.*, 2020, **18**, 1–10.



- 225 T. Li, W. Tong, R. Roberts, Z. Liu and S. Thakkar, *Chem. Res. Toxicol.*, 2020, **34**, 550–565.
- 226 M. Chierici, M. Francescato, N. Bussola, G. Jurman and C. Furlanello, *Biol. Direct*, 2020, **15**, 1–10.
- 227 C. Feng, H. Chen, X. Yuan, M. Sun, K. Chu, H. Liu and M. Rui, *J. Chem. Inf. Model.*, 2019, **59**, 3240–3250.
- 228 B. P. Smith, L. S. Auvil, M. Welge, C. B. Bushell, R. Bhargava, N. Elango, K. Johnson and Z. Madak-Erdogan, *Sci. Rep.*, 2020, **10**, 1–27.
- 229 V. M. Lauschke, *Drug Metab. Rev.*, 2021, 1–8.
- 230 P. Kohonen, J. A. Parkkinen, E. L. Willighagen, R. Ceder, K. Wennerberg, S. Kaski and R. C. Grafström, *Nat. Commun.*, 2017, **8**, 1–15.
- 231 Y. Igarashi, N. Nakatsu, T. Yamashita, A. Ono, Y. Ohno, T. Urushidani and H. Yamada, *Nucleic Acids Res.*, 2015, **43**, D921–D927.
- 232 L. Li, H. Knutsdottir, K. Hui, M. J. Weiss, J. He, B. Philosophie, A. M. Cameron, C. L. Wolfgang, T. M. Pawlik, G. Ghiaur, A. J. Ewald, E. Mezey, J. S. Bader and F. M. Selaru, *JCI Insight*, 2019, **4**, e121490.
- 233 E. Ho, S. Van Hees, S. Goethals, E. Smits, M. Huizing, S. Francque, B. De Winter, P. Michielsen and T. Vanwolleghem, *Front. Med.*, 2019, **6**, 183.
- 234 J. F. Dekkers, C. K. van der Ent and J. M. Beekman, *Rare Dis.*, 2013, **1**, 939–945.
- 235 S. A. Dugger, A. Platt and D. B. Goldstein, *Nat. Rev. Drug Discovery*, 2018, **17**, 183–196.
- 236 M. Matano, S. Date, M. Shimokawa, A. Takano, M. Fujii, Y. Ohta, T. Watanabe, T. Kanai and T. Sato, *Nat. Med.*, 2015, **21**, 256–262.
- 237 M. D. Sarker, S. Naghieh, N. K. Sharma and X. Chen, *J. Pharm. Anal.*, 2018, **8**, 277–296.
- 238 N. Annabi, J. W. Nichol, X. Zhong, C. Ji, S. Koshy, A. Khademhosseini and F. Dehghani, *Tissue Eng., Part B*, 2010, **16**, 371–383.
- 239 M. Nomi, A. Atala, P. De Coppi and S. Soker, *Mol. Aspects Med.*, 2002, **23**, 463–483.
- 240 T. Takebe, R. Imai and S. Ono, *Clin. Transl. Sci.*, 2018, **11**, 597–606.
- 241 J. Vamathevan, D. Clark, P. Czodrowski, I. Dunham, E. Ferran, G. Lee, B. Li, A. Madabhushi, P. Shah, M. Spitzer and S. Zhao, *Nat. Rev. Drug Discovery*, 2019, **18**, 463–477.
- 242 P. Pound and M. Ritskes-Hoitinga, *J. Transl. Med.*, 2018, **16**, 1–8.
- 243 S. J. Hollister, *Nat. Mater.*, 2005, **4**, 518–524.

